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ABSTRACT
Targeted therapy to cancer acts on the molecular abnormalities driving a specific
tumor. In clinical use, targeted therapies can lead to an impressive, but ultimately
short-lived regression of solid tumors: In virtually all cases, a therapy-resistant
tumor arises during targeted therapy, thus limiting its long-time efficacy. From
a population dynamics perspective, the failure of targeted mono-therapy is in-
evitable: a sufficiently large population of tumor cells contains therapy-resistant
mutants as part of its standing genetic heterogeneity. Therapy then selects re-
sistant mutants leading to a tumor consisting of resistant cells. As resistance to
targeted therapy can be caused by diverse molecular mechanisms, targeting one
particular resistance mechanism only leads to the emergence of resistance via an-
other. If targeted therapy is to achieve a long-term tumor remission, it needs to
address all resistance mechanisms present in a population of cancer cells.
As a proof of principle, we systematically derive cell lines resistant to combina-
tions of targeted agents from PC9 cells, a well-studied lung cancer cell line. By
characterizing the respective resistant lines, we show that several distinct resis-
tance mechanisms exist simultaneously in the cell population prior to treatment.
We derive four cell lines driven by different resistance mechanisms. A drug com-
bination targeting all these mechanisms prevents indefinitely the expansion of re-
sistant cells. Our findings explain why, for solid tumors, long-term control of the
disease with targeted therapy has proven elusive so far and point to a treatment
strategy differing from current clinical practice: Instead of keeping the treatment
fixed until a relapse occurs, tumor evolution has to be anticipated by targeting a
broad spectrum of possible resistance mechanisms as early as possible. Our it-
erative protocol offers a generic approach to explore the spectrum for resistance
mutations and can be applied to cell lines driven by different molecular mecha-
nisms.
However, large populations also contain non-dividing cells in a drug tolerant
state, which a curative treatment would need to eradicate. To study this type of
phenotypic heterogeneity, we develop a statistical model to infer growth rates in
a population from single-cell lifetime measurements. Our method offers a way
to study the dynamics of drug tolerant cells and, if applied to cancer data, could
clarify to what extent the drug tolerant state is heritable.
KURZZUSAMMENFASSUNG
Zielgerichtete Krebstherapie wirkt auf die molekularen Anomalien, die das Wachs-
tum eines bestimmten Tumors antreiben. Klinisch kann zielgerichtete Krebsthe-
rapie zu einem beeindruckenden Ru¨ckgang von Tumoren fu¨hren, welcher aber
nur von kurzer Dauer ist: In praktisch jedem Fall tritt wa¨hrend der Therapie
Resistenz auf, was den langfristigen Nutzen der Therapie begrenzt. Aus Sicht
der Populationsdynamik ist das Versagen von zielgerichteter Krebstherapie mit
nur einem Medikament unausweichlich: Eine genu¨gend große Population an Tu-
morzellen entha¨lt als Teil ihrer genetischen Heterogenita¨t Mutanten, welche auf
das Medikament resistent sind. Die Therapie selektiert somit resistente Zellen,
was zu einem neuen, resistenten Tumor fu¨hrt. Weil Resistenz auf zielgerichtete
Therapie normalerweise durch verschiedene molekulare Mechanismen auftreten
kann, fu¨hrt eine Therapie, welche auf nur einen bestimmten Resistenzmechanis-
mus zugeschnitten ist, lediglich zum Auftreten von Resistenz u¨ber einen anderen
Mechanismus. Daher mu¨ssten, wenn zielgerichtete Therapien zu einem langfristi-
gen Tumorru¨ckgang fu¨hren sollen, alle Resistenzmechanismen, welche in einer
Krebszellpopulation existieren, beru¨cksichtigt werden.
Fu¨r einen Grundsatzbeweis isolieren wir systematisch Zelllinien, welche resistent
auf Kombinationen von zielgerichteten Medikamenten sind. Als Modellsystem
nutzen wir PC9 Zellen, eine bekannte Lungenkrebszelllinie. Indem wir die je-
weiligen resistenten Linien charakterisieren, zeigen wir, dass bereits vor Beginn
der Therapie verschiedene Resistenzmechanismen gleichzeitig in einer Population
existieren. Wir leiten vier resistente Linien ab, die alle einen unterschiedlichen
Mechanismus aufweisen. Eine Medikamentenkombination, die auf all diese Me-
chanismen abzielt, verhindert das Auftreten weiterer Resistenzen. Unsere Ergeb-
nisse erkla¨ren, warum die langfristige Kontrolle von Tumoren mit zielgerichteter
Therapie bislang nicht erfolgreich war und legen eine neue Behandlungsstrate-
gie nah: Anstatt bei konstanter Therapie auf einen Ru¨ckfall zu warten, sollte
der Evolution des Tumors zuvorgekommen werden, indem die Therapie so fru¨h
wie mo¨glich neben dem Wildtyp auch auf ein breites Spektrum an mo¨glichen
Resistenzmechanismen abzielt. Unser iteratives Protokoll bietet eine generelle
Herangehensweise, mit welcher man das Resistenzspektrum verschiedener Zel-
llinien untersuchen kann.
Dennoch enthalten große Populationen neben resistenten Mutanten auch Zellen,
die sich nicht oder nur sehr langsam teilen, aber die Therapie u¨berleben. Diese
”schlafenden Zellen” mu¨ssten durch eine kurative Therapie ebenfalls beseitigt wer-
den. Um diese Art der pha¨notypischen Heterogenita¨t zu untersuchen, entwickeln
wir ein statistisches Modell, mit dem wir Wachstumsraten aus der Messung von
Lebenszeiten einzelner Zellen inferieren ko¨nnen. Unsere Methode kann dazu
genutzt werden, die Dynamik der schlafenden Zellen zu charakterisieren und
festzulegen, ob dieser Zellzustand vererbt werden kann.
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1 A SHORT INTRODUCT ION TO THEB IOLOGY OF CANCER
The human body consists of around 1013 cells [1] that are organized in tissues
which make up the different organs. Even though each cell stems from the same
fertilized egg and thus (except for gametes) carries the same genetic information,
cells specialize and form tissues that exhibit different functions. This is achieved
via gene expression patterns that vary from cell type to cell type, meaning that not
all genes that code for proteins are transcribed in all cells: Whereas a brain cell
and a skin cell of the same organism are genetically nearly identical, very different
proteins are made in either cell. Obviously, tissues in different parts of the body
have distinct functions, but they all need to fulfill some basic requirements. Most
importantly, they have to be stable and conserve their function during the lifetime
of the organism.
Usually, the lifetime of a cell is smaller than the lifetime of the whole organism,
which implies that all tissues have to be regularly renewed. This renewal happens
at very different time scales: Whereas nerve cells last nearly a lifetime without
replacement, cells lining the intestine live in a hostile environment and need to be
replaced every few days. So in a living organism, cells divide and die all the time.
This process needs to be strictly regulated to preserve the organization and thus
function of the tissue.
There are three major contributions how well-organized tissue renewal is achieved
[2]. First, there exists a cell memory. Each cell has stable patterns of gene expression
characteristic for its specific type. This pattern has been inherited from ancestral
cells and has already been established during embryonic development. This pre-
serves the diversity of cell types in the tissue. Second, cells perform selective cell-
to-cell adhesion, meaning that cells do not stick equally well to all other cell types.
They rather adhere specifically to some types, which prevents chaotic mixture of
cells in tissues. Finally, cell communication is the last major contribution to orga-
nized tissue renewal. Cells are covered with receptors that constantly sense the
surroundings for proliferative or anti-proliferative signals: They only reproduce if
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Genetic disease: mutations make normal cells „cancerous“ 
‣ allow uncontrolled growth 
‣ avoid cell death 
‣ grow blood vessels to supply nutrients 
‣ allow for unlimited cell division 
‣ invade other organs 
Formation of a tumours consisting of up to 1011 cells.
What is cancer?
Normal cells Cancer cells
Figure 1: Each tumor is initiated from a single mutated and quickly dividing cell which
is no longer subject to the strict controls of tissue formation and renewal. Over
the time, a large amount of cancerous cells develops that disturb normal tissue
function (sketch adapted from www.cancerresearchuk.org).
they receive the respective signals. They enter apoptosis if they receive signals to
die. In this way, new cells are only created when and where they are needed.
If single cells occasionally disrespect the strict rules, the organism does not
experience major problems. Only if cells systematically reproduce in places where
they should not and the control mechanisms fail at stopping this behavior, first
the initial tissue and later the whole organism can be affected. In that case the
organism experiences a disease that is called cancer.
1.1 tumors in the human body
Cancer is a term for a broad class of related diseases in which uncontrolled cell
growth leads to the emergence of abnormal or neoplastic tissue that forms tumors
(see Fig. 1). Depending on where a tumor grows and how big it is, its mere
physical presence is a threat to the organism. In the brain, for instance, tumors
repress healthy tissue, which leads to neurological failures. In the lung, tumorous
tissue disturbs oxygen intake. In the digestive system, tumors block routes for
nutrient intake. In later stages, tumors even acquire the ability to invade into
other tissues, a process called metastasis. The invasion leads to many tumors that
are growing in the body at the same time. If metastatic cancers are left untreated,
they usually lead to the death of the organism.
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1.1.1 Cancer is a genetic disease
The reason for the abnormal and harmful behavior of cancer cells can be found in
their genomes. Cancer cells accumulate thousands of mutations, some of which
occur in genes that control cell proliferation. This leads to the transcription of
malfunctioning proteins.
There are different ways in which mutations can make cells cancerous, and they
often involve genes whose products participate in cellular signaling. A mutation
can affect a cellular receptor such that it permanently folds into a state which sig-
nals a growth signal, even in absence of an external stimulus from a ligand. The
corresponding receptor is an example of an oncogene, and the mutation is termed
a gain-of-function mutation. Alternatively, a mutation can interfere with the proper
function of a protein involved in the control of cellular proliferation. Such a gene
is called a tumor suppressor and the mutation is an example of a loss-of-function mu-
tation. In both cases it is mutations in specific genes that are key to the emergence
of cancer.
Mutations or sets of mutations that make cells cancerous can be acquired in
several ways. Sometimes, a predisposition to cancer is inherited: about 5− 10%
of all human cancers are caused by germline mutations that are passed from one
generation to the next [3]. This explains why in some families there is an accumu-
lation of specific cancer types, such as breast or ovarian cancer. More frequently
however, cancer is triggered by somatic mutations, mutations that occur during the
lifetime of an organism. Often, environmental factors increase the risk of cancer:
Carcinogenic substances such as tobacco smoke [4] or UV radiation [5] induce
DNA damage leading to cancerous mutations, causing for instance lung or skin
cancer. About 12% of all human cancers are due to oncoviruses [6], viruses such as
the Epstein–Barr (EBV) virus or the human papillomavirus (HPV) that can insert
oncogenic genes into infected cells.
In all other cases, cancerous mutations occur just by chance due to unavoidable
errors in DNA replication. The body usually has a very efficient machinery to
check for errors and malfunctioning cells, but this mechanism does not work per-
fectly. During the lifetime the human organism experiences approximately 1016
cell divisions [1]. Any error detection rate larger than 10−16 inevitably leads to the
occurrence of mutations, some of which can cause cancer. Most unambiguously,
pediatric cancers that occur very early in the life of the patients and that are not
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number and thus maintenance of normal tissue architecture and
function. Cancer cells, by deregulating these signals, become
masters of their own destinies. The enabling signals are
conveyed in large part by growth factors that bind cell-surface
receptors, typically containing intracellular tyrosine kinase
domains. The latter proceed to emit signals via branched intra-
cellular signaling pathways that regulate progression through
the cell cycle as well as cell growth (that is, increases in cell
size); often these signals influence yet other cell-biological prop-
erties, such as cell survival and energy metabolism.
Remarkably, the precise identities and sources of the prolifer-
ative signals operating within normal tissues were poorly under-
stood a decade ago and in general remain so. Moreover, we still
know relatively little about the mechanisms controlling the
release of these mitogenic signals. In part, the understanding
of these mechanisms is complicated by the fact that the growth
factor signals controlling cell number and position within tissues
are thought to be transmitted in a temporally and spatially regu-
lated fashion from one cell to its neighbors; such paracrine
signaling is difficult to access experimentally. In addition, the
bioavailability of growth factors is regulated by sequestration in
the pericellular space and extracellular matrix, and by the actions
of a complex network of proteases, sulfatases, and possibly
other enzymes that liberate and activate them, apparently in
a highly specific and localized fashion.
The mitogenic signaling in cancer cells is, in contrast, better
understood (Lemmon and Schlessinger, 2010; Witsch et al.,
2010; Hynes and MacDonald, 2009; Perona, 2006). Cancer cells
can acquire the capability to sustain proliferative signaling in
a number of alternative ways: They may produce growth factor
ligands themselves, to which they can respond via the expres-
sion of cognate receptors, resulting in autocrine proliferative
stimulation. Alternatively, cancer cells may send signals to stim-
ulate normal cells within the supporting tumor-associated
stroma, which reciprocate by supplying the cancer cells with
various growth factors (Cheng et al., 2008; Bhowmick et al.,
2004). Receptor signaling can also be deregulated by elevating
the levels of receptor proteins displayed at the cancer cell
Figure 1. The Hallmarks of Cancer
This illustration encompasses the six hallmark
capabilities originally proposed in our 2000 per-
spective. The past decade has witnessed
remarkable progress toward understanding the
mechanistic underpinnings of each hallmark.
surface, rendering such cells hyperre-
sponsive to otherwise-limiting amounts
of growth factor ligand; the same
outcome can result from structural alter-
ations in the receptor molecules that
facilitate ligand-independent firing.
Growth factor independence may also
derive from the constitutive activation of
components of signaling pathways oper-
ating downstream of these receptors,
obviating the need to stimulate these
pathways by ligand-mediated receptor
activation. Given that a number of distinct downstream signaling
pathways radiate from a ligand-stimulated receptor, the activa-
tion of one or another of these downstream pathways, for
example, the one responding to the Ras signal transducer,
may only recapitulate a subset of the regulatory instructions
transmitted by an activated receptor.
Somatic Mutations Activate Additional Downstream
Pathways
High-throughput DNA sequencing analyses of cancer cell
genomes have revealed somatic mutations in certain human
tumors that predict constitutive activation of signaling circuits
usually triggered by activated growth factor receptors. Thus,
we now know that !40% of human melanomas contain
activating mutations affecting the structure of the B-Raf protein,
resulting in constitutive signaling through the Raf to mitogen-
activated protein (MAP)-kinase pathway (Davies and Samuels
2010). Similarly, mutations in the catalytic subunit of phosphoi-
nositide 3-kinase (PI3-kinase) isoforms are being detected in
an array of tumor types, which serve to hyperactivate the PI3-
kinase signaling circuitry, including its key Akt/PKB signal
transducer (Jiang and Liu, 2009; Yuan and Cantley, 2008). The
advantages to tumor cells of activating upstream (receptor)
versus downstream (transducer) signaling remain obscure, as
does the functional impact of crosstalk between the multiple
pathways radiating from growth factor receptors.
Disruptions of Negative-Feedback Mechanisms that
Attenuate Proliferative Signaling
Recent results have highlighted the importance of negative-
feedback loops that normally operate to dampen various types
of signaling and thereby ensure homeostatic regulation of the
flux of signals coursing through the intracellular circuitry (Wertz
and Dixit, 2010; Cabrita and Christofori, 2008; Amit et al.,
2007; Mosesson et al., 2008). Defects in these feedback mech-
anisms are capable of enhancing proliferative signaling. The
prototype of this type of regulation involves the Ras oncoprotein:
the oncogenic effects of Ras do not result from a hyperactivation
of its signaling powers; instead, the oncogenic mutations
affecting ras genes compromise Ras GTPase activity, which
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Figure 2: With their hallmarks of cancer Hanahan and Weinberg identified general prin-
ciples necessary for tumor formation valid for all tumor types. Their analysis
made clear that several genetic alterations have to occur before a cell becomes
fully malignant (sketch taken from [7]).
driven by any germline mutations are caused by random mutations without any
link to environmental influences.
1.1.2 The hallmarks of ancer
Over decades of cancer research, a broad and very detailed knowledge about dif-
ferent cancer types has been accumulated. Tumorigenesis is a multi-step process,
where several genetic alterations have to occur in a cell before it b comes fully
malignant. In an attempt to simplify and structure the known facts, Hanahan
and Weinberg [8] collected general observations that are true for all cancers, in-
dependent of their tissue of origin (see Fig. 2). In their original formulatio they
identified six of such hallmarks of cancer, which were complemented by four ad-
ditional characteristics in a second review article that was published eleven years
later [7]. In the following, we briefly summarize these un fying fea ures describ-
ing the nature of cancer. A much more detailed discussion can be found in the
original publications and the references therein.
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sustaining proliferative signals. Healthy cells need external stimulus to
divide, for instance induced by growth factors that bind to cell surface receptors.
Cancerous cells do not depend on external signals but permanently proliferate:
They are self-sufficient in their growth signals.
evading growth suppressors. Closely related to the first hallmark is the
fact that cancerous cells also ignore anti-proliferative signals: Signaling circuits
that stop healthy cells from excessive growth through binding of growth suppres-
sor are modified in cancers such that the negative regulation of cell proliferation
is disrupted.
resisting cell death. Usually, there exists a control machinery in cells sens-
ing abnormalities, for example the tumor suppressor TP53. If errors such as DNA
damage are detected, the cell is forced to enter a program of controlled death
which is called apoptosis. Tumors can escape these mechanisms, for instance by
the deletion or loss-of-function mutations in important tumor suppressors such as
TP53.
inducing angiogenesis. All cells require an adequate supply of oxygen and
of nutrients. Tumors that grow excessively cannot be sufficiently provided by the
normal blood vessels of the tissue. Usually, angiogenesis (meaning blood vessel
formation) extending this supply is strictly regulated. But tumors acquire the
ability to actively induce angiogenesis to build their own nutrient supply and
facilitate fast growth.
enabling replicative immortality. Normal cells cannot divide indefinitely.
During each cell division, nucleotide sequences protecting the ends of the chro-
mosomes (the so-called telomeres) shorten. In this way, healthy cells age, a process
that inhibits excessive growth independently of cell-to-cell signaling. Tumor cells
on the other hand can be immortalized by activating mechanisms to maintain their
telomeres above the critical length.
activating invasion and metastasis. Healthy cells stay in the tissue where
they belong. Cancer cells by contrast have the ability to travel through the blood or
lymph system to invade tissues all over the body. This process is called metastasis.
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Apart from the six classical hallmarks, two further characteristics seem to be
particularly important for tumor formation. Among the cellular alterations allow-
ing for excessive growth, also adjustments in the energy metabolism are widely
observed in cancer cells. This metabolic switch has already been described in 1923
by Otto Warburg [9] (and is for this reason termed Warburg effect). Cancer cells
gain energy by processing glucose in a way healthy cells only do under anearobic
(and thus stressful) conditions. As the altered metabolism is very inefficient, en-
ergy metabolism was long thought to be a weakness of cancer cells. By contrast,
more recent findings indicate that the altered metabolism facilitates the biosynthe-
sis of components (such as nucleotides, amino acids, and lipids) that are necessary
for cell replication [10] and thus actively contributes to tumorigenesis. The exact
mechanism though remains elusive so far.
Another important issue is the interaction between tumors and the immune sys-
tem. The immune system is able to recognize and destroy many cancer cells even
before larger tumors form: Experiments in immunodeficient mice have shown that
they develop more tumors than mice with an intact immune system when exposed
to carcinogenic substances [11]. Consequently, solid tumors that actually form in
hosts with a functioning immune system somehow evade immune destruction. The
current understanding is that immunogenic tumors (tumors that provoke a strong
immune response) can be attacked by the immune system and disappear before
they are even diagnosed, whereas weakly immunogenic tumors are not detected
by the immune system and can continue to grow. So it seems to be a necessary
condition to efficiently hide from the immune system to enable tumor formation.
Altogether, many independent steps are involved in the formation of a tumor.
Healthy cells are usually well protected from major damage through a powerful
genomic maintenance machinery and a surveillance system that detects malfunc-
tioning behavior and forces affected cells to die. Therefore, it is surprising that
cells can acquire all of the alterations that are necessary for tumor formation. The
reason why it is still possible are two enabling hallmarks that simplify the required
changes in tumorigenesis.
genome instability and mutation. Most importantly, tumors are genomi-
cally unstable. This means that the rate at which point mutations and also major
chromosomal rearrangements occur is much higher than in non-cancerous cells
[12]. The loss of the tumor suppressor TP53, for instance, enables cells to resist
cell death. Consequently, cells with compromised genomes are able to further
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proliferate without intervening systems that monitor genomic integrity. Hence,
defects in the genome maintenance and repair systems offer selective growth ad-
vantages: The more severe the DNA supervision machinery is affected, the easier
and faster mutated cells can expand.
tumor-promoting inflammation. Increasing evidence is also pointing to
the important role of the tumor micro-environment during tumor formation. Vir-
tual every neoplastic lesion is densely infiltrated with cells of the immune system,
indicating an inflammation of the surrounding tissue. Historically, physicians and
pathologists thought that this behavior was the attempt of the immune system
to fight cancerous cells. Whereas it is indeed true that the immune system can
detect tumor cells and trigger an anti-tumor defense, the immune response also
contributes to the acquisition of the hallmark capabilities: It has been shown that
the acute inflammation supplies bioactive molecules such as growth factors or
pro-angiogenic factors to the tumor environment which is exploited by cancerous
cells [13]. Moreover, chemicals that are actively mutagenic are released by inflam-
matory cells [14], which further accelerates the rate at which new mutations are
acquired. As such, tumor-promoting inflammation is another enabling hallmark.
1.1.3 Example: Overactive EGFR signaling
Whereas all of the different hallmarks of cancer are necessary for tumor formation
and survival, they are acquired at different times and via different mechanisms
in each tumor. To give a concrete example how cells can become self-sufficient in
growth signaling, we briefly discuss the disruption of cell signaling by an overac-
tive growth factor receptor called EGFR.
The epidermal growth factor receptor (EGFR or ERBB1) is part of the ERBB family
of cell surface receptor tyrosine kinases. The ERBB receptors are trans-membrane
molecules that mediate signals between the epithelium (the tissue lining the outer
surface of organs and blood vessels) and the connective tissue. The receptors are
part of the ERBB signaling network [15], which is a layered network: Receptor-
ligand binding initiates cellular signaling cascades that produce a physiological
outcome. It is structured as follows (see Fig. 3): The input layer consists of recep-
tors and their ligands. Binding of a ligand to a receptor monomer induces receptor
dimerization and phosphorylation of the receptor tail within the cell. The signal-
8 a short introduction to the biology of cancer
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R E V I EW S
A network of networks?
The ErbB network might integrate not only its own
inputs but also heterologous signals, including hor-
mones, neurotransmitters, lymphokines and stress
inducers29 (FIG. 1). Many of these trans-regulatory inter-
actions are mediated by protein kinases that directly
phosphorylate ErbBs, thereby affecting their kinase
activity or endocytic transport29. The most extensively
studied mechanism involves activation of G-protein-
coupled receptors (GPCRs) by agonists such as
lysophosphatidic acid (LPA), carbachol (which specifi-
cally activates muscarinic acetylcholine receptors) or
thrombin (FIG. 2).
Experiments done with mutants and inhibitors of
ErbBs imply that the mitogenic activity of some GPCR
agonists requires transactivation of ErbB proteins.
These agents increase tyrosine phosphorylation of
ErbB1 and ErbB2, either by increasing their intrinsic
apoptosis (FIG. 1). Output depends on cellular context, as
well as the specific ligand and ErbB dimer. This has
been best shown in terms of mitogenic and transform-
ing responses: homodimeric receptor combinations are
less mitogenic and transforming than the correspond-
ing heterodimeric combinations, and ErbB2-containing
heterodimers are the most potent complexes21–23 (FIG. 3).
Perhaps the best example of the ability of the ErbB
module to tune mitogenic signalling is provided by the
ErbB2–ErbB3 heterodimer: although neither ErbB2
nor ErbB3 alone can be activated by ligand, the het-
erodimer is the most transforming24,25 and mitogenic21
receptor complex. The ErbB2–ErbB3 heterodimer also
increases cell motility on stimulation with a ligand26;
but the other NRG receptor, ErbB4, which exists in sev-
eral isoforms, has been associated with processes vary-
ing from cellular chemotaxis27 to proliferation and dif-
ferentiation28.
Figure 1 | The ErbB signalling network. a | Ligands and the ten dimeric receptor combinations comprise the input layer.
Numbers in each ligand block indicate the respective high-affinity ErbB receptors8. For simplicity, specificities of receptor binding
are shown only for epidermal growth factor (EGF) and neuregulin 4 (NRG4). ErbB2 binds no ligand with high affinity, and ErbB3
homodimers are catalytically inactive (crossed kinase domains). Trans-regulation by G-protein-coupled receptors (such as those
for lysophosphatidic acid (LPA), thrombin and endothelin (ET)), and cytokine receptors is shown by wide arrows. b | Signalling to
the adaptor/enzyme layer is shown only for two receptor dimers: the weakly mitogenic ErbB1 homodimer, and the relatively
potent ErbB2–ErbB3 heterodimer. Only some of the pathways and transcription factors are represented in this layer. c | How
they are translated to specific types of output is poorly understood at present. (Abl, a proto-oncogenic tyrosine kinase whose
targets are poorly understood; Akt, a serine/threonine kinase that phosphorylates the anti-apoptotic protein Bad and the
ribosomal S6 kinase (S6K); GAP, GTPase activating protein; HB-EGF, heparin-binding EGF; Jak, janus kinase; PKC, protein
kinase C; PLCγ, phospholipase Cγ; Shp2, Src homology domain-2-containing protein tyrosine phosphatase 2; Stat, signal
transducer and activator of transcription; RAF–MEK–MAPK and PAK–JNKK–JNK, two cascades of serine/threonine kinases that
regulate the activity of a number of transcription factors.)
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Figure 3: The ERBB signaling network is a layered network transmitting and translating
extracellular signals to physiol gical cellular outcomes. Most important for tu-
morigenesis re the RAS/RAF/MEK/MAPK and PI3K/AKT cascades, th t lead
to cell proliferation and migration (figure taken from [15]).
processing layer consists of intracellular adapter molecules and enzymes that bind
to the phosphorylated tail of the receptors triggering cellular signaling cascades
such as the MAPK or AKT pathways. These signaling cascades translate the extra-
c l ular signal to specific transcriptional programs to the cell nucleus. The output
layer finally produces a physiol gical outcome. Depending on which ligand was
bound to which rec ptor, programs affecting apoptosi , adh sion o differentiation
ar started. Also cell division and mi ration can be trigg red, which is important
for tumorigenesis in some ca cers.
If the receptor EGFR binds to a ligand, it pecifically triggers the PI3K and
MAPK pathways. Both l ad to st ong proliferative and anti- pop ti signals. Con-
sistent with this observation, verexpr ssio and mut tions of EGFR have been
described in many cancers, mostly in carcinomas (tumors that arise from epithelial
cells) [16]. Overexpression of EGFR leads to an increased amount of receptors that
are made within a cell. As a result, small ligand concentrations can already lead
to a strong cellular response [17]. Mutations, on the other hand, alter the struc-
ture of the receptor: Large deletions in the extracellular domain of the receptor
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are commonly observed [18], leading to ligand-independent kinase signaling – the
receptor is stuck in its active state. Both mechanisms lead to constant proliferation
and make cells insensitive to other extracellular signals.
1.1.4 Standard treatment options
The current treatment options that are routinely available for solid tumors are
surgery, radiotherapy and chemotherapy. Clearly, surgery is the oldest and most
straightforward way of treating cancer. For the longest time in the history of
cancer therapy, cutting out tumorous tissue was actually the only way of treating
patients. Its rationale is based on two simple observation. First, small tumors even-
tually develop into large tumors. Second, large tumors tend to metastasize into
other parts of the body, thus exacerbating the tumor burden. In principle, surgery
can be a curative treatment if all cancerous cells are removed. This requirement
already shows its major limitation: Tumors tend to spread into surrounding tissue,
the lymph and the blood system, which is why complete elimination is hard in
practice. Nevertheless, still today it is the most effective treatment if tumors are
locally constrained to a tissue that is surgically accessible.
The second main pillar of cancer management is radiotherapy [19]. Ionizing radi-
ation causes DNA damage and by that leads to cell death. The field of radiation
oncology was initiated after the discovery of X-rays by Wilhelm Conrad Ro¨ntgen
in 1895 [20] and the discovery of radium by Pierre and Marie Curie in 1898 [21].
Both forms of radiation were observed to cause strong skin burn, and first reports
on successful medical use in cancer treatment followed around 1900. At the time,
the major limitations were severe radiation toxicities (radium) and extensive tissue
damage of normal cells (X-rays) due to the limited depth of the low energy beams
that were available. The invention of linear accelerators in the middle of the 20th
century made it possible to use high energy beams that could be confined to small
areas, thus sparing healthy tissue from radiation. Today, advances in imaging and
the possibility to control beam shapes facilitate treatment planning and minimize
side effects. Radiation therapy is often used in combination with surgery to either
shrink the tumor before the operation or decrease the risk of tumor recurrence
afterwards. Nevertheless, side effects such as nausea, infertility or even secondary
cancers due to radiation damage remain major limitations.
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The term chemotherapy originally means the treatment of any disease with chemi-
cal drugs. In the context of cancer, chemotherapy usually refers to cytotoxic drugs
killing cells during cell division. The active development of chemotherapeutic
drugs against cancer started after the observation that soldiers who have been ex-
posed to sulfur mustard gas during World War I suffered from a depletion of the
bone marrow and lymph nodes [22]. Subsequent experiments in mice with lym-
phoid tumors showed that the delivery of mustard gas resulted in tumor regres-
sion. Since then, different classes of chemotherapeutic drugs have been developed,
for instance alkylating agents (such as mustard gas), antimetabolites or cytotoxic
antibiotics. Some cancers such as acute childhood leukemia and Hodgkin’s dis-
ease can be cured with chemotherapy [22]. As compared to surgery or radiation,
chemotherapy has the big advantage of not acting on local parts of the body only:
Mostly delivered intravenously, it targets both the primary tumor and possible
metastases. Today, chemotherapy is often used in combination with surgery or
radiation as adjuvant chemotherapy to minimize the risk of recurrence from cells
surviving the local treatment. Unfortunately, most chemotherapies have severe
side effects ranging from immunosuppression, anemia and hair loss to major or-
gan damages. This is why, even if the use of chemotherapeutic agents can be very
effective, it often drastically reduces the quality of life [23].
1.2 targeted therapies: a novel treatment approach
Driven by more efficient and affordable sequencing methods, many mechanisms
enabling cancer cells to proliferate are known today. The development was accom-
panied by the discovery of oncogene addiction, a term that was first introduced by
Weinstein [24, 25]. Oncogene addiction means that cancer cells, even though they
require several steps before becoming fully malignant, do depend on growth sig-
nals transmitted by single oncogenes. Together with the finding that inactivation
of those oncogenes in healthy cells is often well tolerated, molecular drivers (genetic
alterations cancer cells depend on) were identified as possible vulnerabilities [26].
As advances in drug development allowed to design drugs targeting molecular
drivers, in the last two decades the paradigm in cancer treatment shifted from
cytotoxic chemotherapy to targeted therapy. Whereas classical chemotherapy in-
terferes with all quickly dividing cells, targeted therapy kills cancerous cells of a
specific molecular type only [27], implying significantly less side effects. Targeting
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first year of my pathology residency with Philip Custer in Philadel-
phia (from 1953 to 1954), we had focused primarily on hematopoi-
etic neoplasms. In the Pathology Department of the University of 
Pennsylvania School of Medicine, I used a short-term cell culture 
technique developed by Edwin Osgood and Marion Krippaehne 
(10) to study human leukemic cells. The cells were grown on small 
slides, and I rinsed the cells with tap water before staining them 
with Giemsa to visualize their chromosomes. This was an inad-
vertent use of the “hypotonic technique” to disrupt the mitotic 
spindle and expand the cells, and it resulted in the presence of 
countable chromosomes in my metaphase chromosomal prepara-
tions. I knew nothing about cytogenetics at this time but felt that 
the chromosomal preparations of the leukemic cells warranted 
investigation for any abnormalities. I found no one on our campus 
interested in human chromosomes but was eventually directed to 
a graduate student, David Hungerford, who was working at the 
Fox Chase Cancer Center and attempting to obtain material for a 
thesis on human chromosomes.
Hungerford and I, as well as other researchers around the world, 
began to use the new cytogenetic techniques to determine whether 
human leukemias could be characterized by specific chromosome 
abnormalities. Although we initially found no consistent genetic 
abnormalities in cells from individuals with acute myelogenous leu-
kemia, Hungerford identified a characteristic small chromosome in 
the neoplastic cells of two patients with chronic myelogenous leu-
kemia (CML) (Figure 1) (11). We then began, with the help of Paul 
Moorhead, a scientist at the Wistar Institute, to use an improved air 
drying technique for the cell preparations, which had been developed 
by Rothfels and Siminovitch (12), and were able to report that a series 
of seven patients that we had analyzed all had this minute chromo-
some (13). Tough and colleagues (14), who were also studying human 
leukemias, designated this minute chromosome the “Philadelphia 
chromosome,” in accord with the Committee for the Standardiza-
tion of Chromosomes, which had suggested that abnormal chromo-
somes be named for the city in which they were discovered.
Our observation that all the neoplastic cells in nearly all cases 
of a specific human cancer contained a consistent somatic genetic 
change provided strong evidence to support Boveri’s hypothesis 
(2) that a critical genetic alteration in a single cell, which provided 
the cell with a growth advantage, could give rise to a tumor. How-
ever, in the years immediately before and after the identification 
of the Philadelphia chromosome, consistent chromosomal altera-
tions were not found in other types of leukemia. The only other 
apparent consistent alteration, which was noted in a number of 
patients with chronic lymphocytic leukemia in New Zealand and 
designated the Christchurch chromosome (15), proved not to be 
a somatic alteration but rather a familial abnormality in one par-
ticular family in that area.
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During the 1960s, analysis of some human solid tumors revealed 
that in nearly all types of cancer the chromosome pattern was 
abnormal (16). In particular, extensive chromosome alterations, 
such as chromosome numbers in the hypotetraploid range and 
gross structural chromosome rearrangements, were observed in 
individuals with very advanced tumors and malignant effusions. 
Furthermore, the extent of the cytogenetic changes often correlated 
directly with the extent to which the tumor had progressed clinical-
ly (17) — as had been observed earlier in experimental tumors that 
caused the accumulation of tumor-derived fluid in the abdomen 
(ascites tumors) — with the tumor consisting of a single stem line 
of cells or several closely related sub-lines. However, the presence of 
a consistent chromosome abnormality in all neoplastic cells was 
somewhat less common in solid neoplasms than in the leukemias, 
and in fact, huge variety in the number and type of chromosome 
alterations in a given tumor were often observed (17). Most impor-
tantly, when stem lines were present in solid tumors, they typically 
differed in their chromosome abnormality from one individual 
to another. Indeed, although a proportion of cases of some types 
of tumors, including tumors of the ovaries, testes, and meninges 
(18), show a characteristic chromosome abnormality, these abnor-
malities are not found in sufficient individuals with a given type of 
tumor to be considered a marker chromosome for the neoplasm. 
Thus, no chromosomal change comparable in consistency to the 
Philadelphia chromosome has been observed.
Part of the difficulty of identifying genetic abnormalities charac-
teristic of specific neoplasms was methodological. Although dur-
ing the 1960s technical advancements continued to be made — for 
example, Hungerford and coworkers developed more efficient hypo-
tonic solution methods for generating chromosome preparations, 
and phytohemagglutin was used to stimulate mitotic cell division 
in lymphocyte cultures, thereby providing an easy source of mitotic 
chromosomes from non-neoplastic cells (19) — it was still impos-
sible to individually identify human chromosomes. Furthermore, 
the often poor technical quality of metaphase chromosomal prepa-
rations from tumor material, as opposed to normal cells, made even 
accurate counting of chromosomes sometimes difficult.
Despite the lack of progress in identifying genetic abnormalities 
characteristic of specific neoplasms during the 1960s, other areas 
of research provided evidence to support the concept that chro-
mosome abnormalities are associated with cancer. An increased 
number of spontaneous chromosome breakages were observed to 
occur when chromosome preparations were made from circulating 
normal lymphocytes that had been isolated from individuals with 
inherited clinical disorders associated with an increased risk of 
leukemia and other malignancies such as Bloom syndrome, ataxia 
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Figure 4: The unusual short Philadelphia chromosome was discovered in CML patients
in 1960. The breakpoints of chromosome 9 and 22 are indicated by the black
arrows (picture taken from [29]).
cancer at the molecular level also means a step towards personalized medicine: As tu-
mors in different patients are not necessarily driven by the same genetic alteration
(a fact that is usually referred to as intertumor heterogeneity), tumor classification
needs to take into account the genetic subtype and not only the tissue of origin: For
non-small cell lung cancer (NSCLC) for instance, more than 15 genetic subtypes
have been identified [28] . Most targeted therapies approved today are either small
molecules that can enter the cell membrane or monoclonal antibodies binding to
cell surface proteins.
1.2.1 Gleevec can cure chronic myelogenous leukemia (CML)
The story of Gleevec is the biggest success of targeted therapies so far and was its
major breakthrough: It transformed CML, which is a specific kind of blood cancer,
from a deadly disease to a manageable condition such as diabetes.
Everything started with the discovery of an abnormally short chromosome in
CML patients (see Fig. 4) [30], which was later called Philadelphia chromosome, after
the city where it was discovered. It became clear that the abnormal chromosome
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was caused by the fusion of parts of chromosome 9 and chromosome 22 [31]. More
specifically, the two genes BCR and ABL which are usually not located next to each
other are connected by the fusion [32, 33]. This leads to permanent kinase activity
resulting in the accumulation of immature white blood cells [34]. The big hope at
this point was that, if it is possible to inhibit the overactive signal, cells harboring
the Philadelphia chromosome would die. Over the course of 30 years of research
from initial discovery to understanding the function of the BCR-ABL gene fusion,
a very clear drug target had thus been identified: The overactive kinase domain in
the BCR-ABL fusion gene.
The requirement to develop a kinase inhibitor was a completely new approach
in drug discovery. So far, kinase inhibitors were considered to be inefficient due
to the large number of different kinases existing in cells: An unspecific kinase in-
hibitor would disrupt cell function in an uncontrolled way, and was thus expected
to cause severe side effects in patients. Fortunately, enough variation in the ATP
binding pockets of different kinases was found such that a compound specifically
targeting the BCR-ABL kinase could be developed [35]. Imatinib, what the com-
pound was called later, showed to be lethal for cells with the Philadelphia chromo-
some and completely harmless in all others. Clinically, the relevant observable to
quantify the efficacy of a new treatment is the fraction of patients that respond to
therapy and experience a significant remission. This fraction is called response rate.
The first clinical trials investigating the safety and tolerability of Imatinib in CML
patients treated with Imatinib followed quickly and showed impressive response
rates of close to 100%, with very mild side effects [36]. In 2001, Imatinib was ap-
proved under the trade name Gleevec, and follow-up studies on patients treated
with Gleevec showed an overall survival of 89% after five years [37]. Today, most
CML patients have a very good prognosis: After experiencing two years of remis-
sion, patients have the same life expectancy as people who never had cancer.
Gleevec was the first targeted drug to be approved and used clinically; its over-
whelming success promoted the complete field. Since then, hundreds of small
molecules targeting different parts of cellular signaling pathways have been devel-
oped and tested in patients. However, in all cases other than Gleevec, even if a
subset of patients benefits greatly from specific therapies, the response is typically
short-lived, as we will discuss below.
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1.2.2 The occurrence of resistance limits the long-term efficacy
One challenge in delivering targeted therapies is the identification of patients that
benefit from a specific drug. Actually, CML turned out to be the one example
where the molecular mechanism causing continuous growth is always the overac-
tive kinase in the Philadelphia chromosome. Most other cancers however, even if
classified as the same disease, are genetically much more diverse. This explains
the low response rates in clinical trials on various targeted drugs that followed
after Gleevec: In lung cancer for instance, EGFR is often highly expressed. But
the treatment with an EGFR kinase inhibitor only led to low response rates of ap-
proximately 10%. Only later, mutations in the EGFR kinase domain were found
in the subset of patients responding most strongly to therapy, implying that not
the high expression of EGFR but the specific activating mutations are driving the
tumor [38, 39].
Unfortunately, there is another problem limiting the efficacy of targeted thera-
pies. Even after an initial response (which can be dramatic in some cases, with
macroscopic tumors shrinking to the point where they can no longer be detected),
patients in almost all cases experience a recurrence of the disease within one year:
Tumors that are resistant to therapy grow despite continued treatment. Sequenc-
ing of biopsies from the relapsed tumor usually show genetic alterations such as
point mutations or gene amplifications as compared to the genotype of the initial
tumor which cause resistance [40].
There exist different ways how a tumor can become resistant to targeted therapy.
First, the drug target can be modified by a secondary mutation. In this case, the
drug can no longer bind and the initial growth signal persists. Second, a mutation
can permanently activate a part of the downstream signaling cascade. This means
that the drug binds correctly, but has no growth suppressing effect. Finally, a
bypass track can be activated. The resistant tumor does not depend on the initial
growth signal anymore, which is why it does not respond to therapy. For a review
on resistance mechanisms to targeted EGFR inhibition, for instance, see [41].
While the high specificity of targeted therapies accounts for manageable side ef-
fects and is thus its biggest advantage, it is also the reason why resistance arises so
frequently in practice. Often, a single nucleotide change is enough to confer resis-
tance. Due to unavoidable errors in DNA replication, some genetic heterogeneity
is found in large tumors. Cells carrying resistance mutations therefore inevitably
exist in very low frequencies prior to any kind of treatment if the population size
14 a short introduction to the biology of cancer
is big enough. Targeted therapy then imposes a strong selective pressure favoring
resistant mutants which grow while the sensitive majority of cells dies. Resistant
cells eventually take over the population and cause a relapse. The type of muta-
tions that confer resistance, the stochastic manner in which they arise, and their
statistics is the topic of this thesis.
1.3 physics and theoretical models in cancer
There are many examples where the application of concepts originally used in
the physical sciences contributed valuable insights to different fields of cancer re-
search. For the longest time, physics and medicine have been entangled in the
context of radiation and imaging. Medical physicists run and control the accelera-
tors used to generate radiation. A detailed understanding of the specific resonance
of atoms with magnetic dipoles has led to the development of magnetic resonance
imaging (MRI), which is nowadays routinely used for diagnosis and staging of tu-
mors. Another field is classical biophysics: Cancer cells do not only have disturbed
biochemical signaling networks, but also differ in shape, size and elasticity from
healthy cells [42]. In this context, physicists study how mechanical features con-
tribute to tumor development. The role of physical interactions in the formation
of metastases, for instance, has been investigated extensively [43]. More recently,
the accumulation of large data sets obtained by sequencing poses the challenge to
interpret the data correctly and extract useful information. For gene expression,
the number of measured genes usually exceeds the sample size by far, leading to
noisy data and results that are not robust with respect to the incorporation of new
data [44]. One possible way to overcome this curse of dimensionality is to strive for
a coarse grained picture. This separation of scales is a concept deeply rooted in
theoretical physics and has been applied to cancer data, for example by includ-
ing biological knowledge on the level of signaling pathways for improved disease
classification and prognosis [45].
A completely different connection between physics and cancer emerges from
the dynamics of cancer. Starting from initial mutations allowing the establishment
of a small set of rapidly dividing cells, a tumor evolves under random mutation,
selection for faster growth, and competition for shared resources. As such, tumors
are interesting dynamical systems where a large number of cells responds to envi-
ronmental challenges. Due to the complex interactions (between tumor cells, with
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the micro-environment or also with delivered drugs), the emerging macroscopic
behavior is impossible to understand by characterizing each single constituent on
a molecular level. Different aspects of this dynamics have been investigated: A
mathematical model and extensive simulations, for instance, have been used to
study how new mutations migrate within the dense, three-dimensional architec-
ture of a solid tumor [46]. Regarding the interplay with the immune system, a
fitness model for neoantigens is able to predict if patients respond to immunother-
apy [47]. And in the context of drug resistance, an evolutionary model was used
to determine from circulating tumor DNA if resistant mutants were present in
tumors prior to treatment [48]. There are many other examples, and all of these
approaches have complemented pure biomedical research. In the best case, these
interdisciplinary efforts can lead to improved treatment outcomes.
1.4 outline of this thesis
The focus of this thesis is on the specific mutations which cause resistance to
targeted treatment, and on their stochastic emergence in a large population of
tumor cells. It involves both experimental work on cell cultures and the analysis of
stochastic population genetics models. Key point is that cancer cell populations are
genetically heterogeneous and already small subpopulations of a specific genotype
can lead to the failure of therapy. Therefore, a detailed understanding of the
underlying dynamics is crucial for rational treatment choices. We study tumor
heterogeneity from different perspectives:
• In chapter 2, we use classical population dynamics to model the occurrence
and growth of resistant mutants in a much bigger population of cells sen-
sitive to a particular treatment. We do not only investigate the growth of
individual mutants, but also study the dynamics of colonies or clades – a
subset of mutants initiated by the same mutational event. Specifically, we
are interested in the probability of resistance as a function of population
size, mutation rate and growth rate of the resistant mutants.
• In chapter 3, we introduce an experimental approach based on artificial evo-
lution: For the prospect of cure under targeted therapy, it is indispensable
to know in how many ways a specific cancer cell population of given size
can develop resistance to therapy over a given timescale. In a well studied
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cancer cell line, we iteratively amplify all resistance mechanisms to a specific
targeted therapy in a population of given size. We isolate four different resis-
tant lines and find a set of four compounds to be sufficient to suppress all of
them. By that, we give a proof of principle that at least in our model system
the number of accessible resistance mechanisms is limited. We characterize
the different resistant lines and discuss implications for treatment schedules.
• In chapter 4, we turn to phenotypic heterogeneity. It has been shown that
subpopulations of different growth rates exist simultaneously in cancer cell
populations: Besides quickly proliferating cells, slowly dividing cells have
been observed, that, under therapy, neither grow nor die. The exact role of
these sleeper cells in the development of resistance to therapy is unknown to
date. We develop a statistical model to infer growth rates from single cell
lifetime measurements. If applied to cancer data, our approach could offer
valuable insights in the dynamics of the sleepers.
We close the thesis with a short chapter discussing future research directions.
2 RES ISTANT MUTANTS IN EVOLV INGPOPULAT IONS
2.1 introduction
2.1.1 Growing cancer cells in cell culture
Figure 5: Henrietta Lacks, the woman whose
cells were taken to create the first
ever immortal cell line HeLa
Cancer cell lines offer useful model
systems to investigate tumor evolution
under controlled laboratory conditions.
A human cancer cell line is derived
from a tumor sample of a patient, ob-
tained for instance from a biopsy or
after surgery. Simply put, the tumor
tissue is cut into pieces, cells are sep-
arated with the use of enzymes, trans-
ferred to a culture flask and supplied a
with proper growth medium. If every-
thing goes well, the cells adapt to the
new environment and start to grow.
Compared to non-cancerous cells,
cancer cells are relatively easy to cul-
tivate. The reason is that healthy
cells cannot divide indefinitely: Dur-
ing each cell division, the telomeres – a
repetitive nucleotide sequence capping
the end of each chromosome – of cells shorten. If their length falls below a critical
value (which usually happens after 50-70 divisions), the cells enter programmed
cell death. This natural bound is called the Hayflick limit, named after the micro-
biologist Leonard Hayflick, who experimentally showed that normal cells cannot
reproduce indefinitely [49]. Conversely, most cancers have mutations in genes that
control the enzyme telomerase, which, if activated, adds bases to the end of the
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telomeres and therefore prevents telomere shortening. Indeed, it is one key fea-
ture of cancer cells that they are immortal, in the sense that they can divide beyond
the Hayflick limit. Non-cancerous cells can also be immortalized, for instance by
artificially expressing proteins that prevent degradation of the telomeres. But not
surprisingly, the first ever cultured immortal cell line was a cancer cell line called
HeLa1, which was established in 1952.
Over the last 50 years, thousands of cancer cell lines have been established and
used for research. Of course, there are important differences between tumors and
cell lines. First of all, tumors compete for resources and space with surrounding
tissue. So if a tumor grows, it has to also form new blood vessels which connect
the inner parts of the tumor to the blood supply. Cell cultures, on the contrary,
are well fed with growth medium and can expand freely. Also, a tumor in a living
organism interacts with the immune system. The immune system can recognize
and fight cancerous cells – so what one observes in cell culture without selection
pressure from the immune system might not resemble how the same cells would
have evolved in an organism. To name yet another example, tumor heterogeneity
might not be fully accounted for by cell cultures. As mentioned above, cell lines
originate from small tissue samples. Tumors, however, are spatially heterogeneous,
so a sample taken from one end of the tumor might behave differently compared
to a sample taken from another end or even a metastasis.
Despite these limitations, cancer cell lines can be seen as molecular models for
tumors: Especially in the 1990s, when high throughput techniques in sequencing
were developed and sequencing whole exomes or even genomes started to be
affordable, cancer cell lines helped to shed light onto genetic mechanisms driving
different cancers. As cancer cell lines are easy and cheap to grow, the impact of
different drugs could be studied systematically and sensitivities could be mapped
to genetic alterations. By that, many driver mutations have been identified and it
1 The name HeLa stands for Henrietta Lacks, who was an American woman suffering from cervical
cancer. She died in 1951 at the age of 31. During a biopsy, tumor tissue was taken from her and
George Gey succeeded in creating an immortal cell line from the sample, which he called HeLa.
Over the years, HeLa cells became very popular: they were for instance used to find a polio vaccine
and were the first human cells ever to be cloned. Still today, HeLa cells are used around the world.
Shockingly, the cell line was created without consent or knowledge of Henrietta Lacks and her
family. The Lacks family learned by chance about the existence of the cell line roughly 25 years later
which raised a huge discussion about privacy and patient rights. The stunning story of Henrietta
Lacks and HeLa cells can be found in the book ”The immortal life of Henrietta Lacks” by Rebecca
Skloot.
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became clear that tumors have to be classified not only by their tissue of origin but
also by their genotype.
2.1.2 Handling cancer cell lines
To perform a series of experiments on a cell line, one needs a constant supply of
cells. To this end, cells need to be cultured over several weeks or months. Of
course, one aims at comparing results of experiments that have been conducted
at different time points. Therefore it is important to keep the growth conditions
as constant as possible. To minimize effects that alter the population, for instance
strong selection induced by heavy competition for shared resources, cells are kept
permanently in an exponential growth phase, where they have enough space and
nutrients to grow. This means that the population needs to be split regularly and
provided with new growth medium (one to two times per week, depending on
how fast the cells grow).
Cells that are cultured in vitro can either grow in suspension, which means that
they float in their culture medium, or adherently, which means that viable cells
attach to the bottom layer of the culture flask. Which type of growth is observed
depends on the specific cell line that is chosen for culture (HeLa cells for instance
grow in suspension, whereas PC9 cells, which are used in the experiments done
for this thesis, grow adherently). For suspension cells, splitting is easily done by
simply removing a part of the growth medium (including cells) and refilling the
culture flask with fresh growth medium. For adherent cultures, one first needs to
detach the cells, which is usually done with the help of specific enzymes. After
that, the cell suspension is mixed, a part is taken out and the remaining population
is provided with fresh growth medium. Over night, the cells adhere again to the
bottom of the culture flask. The part of the population that has been separated
can now be used for experiments. For instance, the response to drugs can be
examined with various assays, or DNA of the cells can be sequenced to determine
their genotype. One cycle of seeding a culture, exponential expansion and then
splitting is called a passage.
If one passages cancer cells over long times, the population evolves and genetic
mutations occur by random errors in DNA replications. If something vital is
hit, the cells grow much slower so that over time, the mutation is removed from
the population. Of course, also a beneficial mutation can occur; in this case, the
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mutated cells will grow faster than the wild type and over time take over the
population. But most mutations tend not to have a huge impact on the fitness of
the cells. This means, that over time, a certain degree of genetic variation within
the population is created. This is important when it comes to drug sensitivity.
Some mutations can – just by chance – confer resistance to a treatment which the
parental type is susceptible to. Naturally one assumes that resistance comes with
some sort of fitness disadvantage. To give a concrete example why this assumption
is reasonable: PC9 cells are driven by an overactive receptor which is stuck in an
active state even without external stimulus. The cells are sensitive to a drug that
binds to the ATP binding pocket of the receptor and thus silencing it. The best
studied resistance mechanism for this cell line is a single nucleotide change that
alters the binding pocket a little bit, massively increasing the binding affinity for
ATP as compared to the one for the drug. The drug thus no longer binds to that
pocket. As the ATP metabolism is disrupted, cells harboring the mutation can still
grow, but divide slower. If one has a cell line that is susceptible to some kind
of drug, one can think of it as a system in which two types of cells coexist: A
sensitive bulk (everything without a resistance mutation) and a resistant minority
(everything with some resistance mutation), which usually grows a bit slower than
the parental cell type.
We are interested in characterizing the dynamics of resistant mutants in a much
bigger sensitive population, so we aim at determining the number of mutant cells.
Unfortunately, this number is hard to measure experimentally: One can visually
not discriminate between sensitive and resistant cells. Only after treatment it be-
comes clear which cells were resistant, since only these survive. Moreover cells
can only be seen and counted under the microscope. But with a microscope it
is hard to visualize the whole growth area. Practically, it is therefore not feasible
to monitor the total number of resistant cells in a large population. So it is hard
to compare theoretical predictions with experimental data. But there is another
interesting value which is directly accessible: The number of resistant colonies.
The cell line we use in the experimental part of this work grows adherently. If
a resistance mutation occurs in one cell at some point in time, the cell is spatially
fixed. The mutation will only migrate via cell division, and cells carrying the
mutation form a colony. As resistant cells typically grow more slowly than the
sensitive wild type, most of the colonies will die out over time because they are
out-competed by the sensitive cells. The situation changes if one starts to treat the
population. Most of the cells, the sensitive majority, dies but the resistant colonies
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population size
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Population size dependent colo y formation
3 weeks after treatment startFigure 6: (left) A population of parental PC9 cells as seen under the microscope. As
the scale bar implies, each cell has a diameter of approximately 10-20µm. At
this point it is not possible to discriminate between sensitive and resistant cells.
(right) After treatment pre-existing resistant cells survive and expand. The re-
sulting colonies can be detected as gray spots by the naked eye. Details of the
experiments leading to these pictures are given in chapter 3.
existing at that time survive. The small colonies can expand exponentially because
there is no longer competition from surrounding cells. If one waits long enough,
cell density will be very high in the vicinity of resistant cells existing prior to
treatment and very low everywhere else. As shown in Fig. 6 resistant colonies are
visible to the naked eye as gray spots. By counting those spots one can measure the
number of resistant colonies existing prior to treatment 2. Therefore, investigating
the number of colonies instead of the total number of resistant cells has the crucial
advantage of being easily observable.
2.1.3 Mathematical models of cancer resistance
Initially, the evolution of resistant mutants in expanding populations has been
investigated in the context of bacterial resistance to antibiotics. Salvatore Luria
and Max Delbru¨ck performed a classic experiment to answer the question whether
bacteria acquired phage-resistant mutations spontaneously at any time during the
expansion (H1, random mutation hypothesis) or due to adaptation when being
exposed to the phage (H2, adaptive mutation hypothesis) [50]. Their big insight
was that the two hypotheses define very different stochastic processes: Whereas
H2 describes a simple binomial process, H1 implies a much broader distribution
2 If the local density becomes very high cells are likely to detach from the container wall. In this
case they spread quickly through the liquid growth medium and initiate new colonies quite distant
from their original position – this introduces a new source of noise in the number of colonies. The
number of colonies therefore cannot be monitored reliably for long times.
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in which the variance exceeds the mean by a factor that grows exponentially with
the expansion time. The reason is that at the beginning of the expansion the
population size is small and an early mutation is very unlikely to occur. But if it
happens, mutant cells expand exponentially – so the number of mutants observed
at later times is very high. Therefore the expectation value of the number of
mutants is dominated by the rare event of an early mutation.
In their original formulation, Luria and Delbru¨ck considered the growth of sen-
sitive cells and resistant cells deterministically, but treated the mutational process
stochastically. The resulting distribution that describes the number of resistant bac-
teria in an exponentially growing population of sensitive bacteria is today known
as the Luria-Delbru¨ck distribution. As their work did not only settle the funda-
mental question (H1 is the correct hypothesis), but also offered a means to esti-
mate mutation rates, the model has initiated a long history of research ever since.
Important extension have been made by Lea and Coulson [51] who treated the
growth of the resistant mutants stochastically, and by Armitage [52] who derived
the exact probability generating function. These and many other contributions are
discussed in reviews, for instance in [53].
More recently, the Luria-Delbru¨ck model has been utilized to study the evolu-
tion of resistance in cancer. One of the first surveys on the issue was done by
Coldman and Goldie [54], who considered a stochastic model of resistant and sen-
sitive mutants where they included cell death. Coldman and Goldie observed that,
for a given total population size, a large death rate leads to the accumulation of
resistant mutants as compared to growth with zero death rate. The reason is that
for large death rates, it takes longer to reach a fixed population size and there is
more time for resistant mutants to emerge. Iwasa et al. [55] considered the growth
of both the sensitive and the resistant cells as a linear birth-death process where
sensitive cells could mutate with a fixed mutation rate per cell division. Impor-
tantly, the authors found that the probability of resistance, meaning the probability
of observing at least one resistant mutant in the population, increases with the
tumor size at detection and with the mutation rate.
A major limitation of the models mentioned so far is the assumption of expo-
nential population growth. Even if the premise is valid for the early stage of tumor
initiation, growth eventually slows down due to competition for shared resources
when the tumor exceeds a certain size. For this reason, many models have been
developed to study how non-exponential growth influences the mutant dynamics.
One interesting extension for the Luria-Delbru¨ck model was given by Dewanji et
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Figure 7: Growth dynamics in two different settings: In a tumor (left), the population
cannot expand exponentially indefinitely since the maximum number of cells
the environment can host is limited by competition for shared resources. In
cell culture however (right), the population is kept in an exponential phase to
constantly supply new cells for use in experiments.
al. [56], who considered arbitrary but deterministic growth of the sensitive popu-
lation. Against this background, they considered the growth of the mutants as a
stochastic birth death process where the mean of the number of mutants is either
described by an exponential or Gompertzian growth law. Tomasetti [57] showed,
in an even more general approach, that the probability of resistance for a given
tumor size is independent of what type of growth curves is assumed for the mean
size of the tumor. A more complete collection of models concerned with cancer
resistance is given in [58].
2.1.4 Outline of this chapter
In the following, we investigate the population dynamics of resistant mutants in a
population of sensitive cells. In section 2.2 we introduce competition for shared re-
sources, see Fig. 7, left panel. As a minimal model incorporating competition, we
study a population that is confined by a carrying capacity (the maximum number of
individuals the environment can host) which slows down the growth at large pop-
ulation sizes. We consider two types of cells, sensitive and resistant to a particular
treatment. The majority of the population is sensitive and we assume this part to
grow according to a deterministic law. Against this background, we consider the
stochastic emergence of resistant mutants – a similar approach as Lea and Coulson
[51] used to describe the Luria-Delbru¨ck distribution, but with a different growth
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law for the number of sensitive cells. In section 2.3, we focus on the situation of
culturing cells in vitro. To perform consecutive experiments, cells are cultivated
for long times. As shown in Fig. 7 in the right panel, the population experiences
multiple cycles of exponential expansion followed by randomly sampling a subset
of the population and discarding the rest. We first neglect mutations and study
how unfit cell types are lost from the population over time. In a second step, we
survey how resistant cells that are introduced by mutations evolve and can get
fixed in the population.
2.2 semi-stochastic birth-death process with logis-tic growth
In the following, we assume that, without selection pressure, sensitive cells divide
at rate bs and die at rate ds. Analogously, resistant cells divide at rate br and
die at rate dr. At each cell division, there is a small but finite probability µ that
a cell mutates and initiates a resistant sub-population. As explained before, these
mutations occur just by chance and the mutation rate per cell division is extremely
low (approximately 10−7− 10−9 per nucleotide and cell division). We assume that
resistant mutants are less fit than sensitive cells, meaning that resistant mutants
typically grow (at least a little) slower than the sensitive cells. These choices imply
that mutant cells are far outnumbered by the sensitive population. But once under
treatment, only the resistant cells will survive; this is why an understanding of
their dynamics plays a key role for tumor evolution under treatment.
2.2.1 Growth dynamics of the sensitive cells
To model growth constrained by competition, we reduce the rate of cell division as
the population size increases. We focus on the number of sensitive cells Ns, which
are thought to make up the majority of the population. We describe the growth
dynamics of the sensitive population by the following deterministic law
dNs
dt
= bs · (1− µ) ·
(
1−
Ns
K
)
·Ns − ds ·Ns, (1)
2.2 semi-stochastic birth-death process with logistic growth 25
whereNs denotes the number of sensitive cells, bs and ds the birth and death rates
per unit time, µ the mutation rate per cell division, and K the carrying capacity.
This differential equation (1) can easily be solved giving
Ns(t) =
Nmax
1+ω exp(−gst)
, (2)
where we introduced the following definitions:
gs = bs(1− µ) − ds,
Nmax = K
(
1−
ds
bs(1− µ)
)
,
ω =
Nmax
N0
− 1, with N0 = Ns(t = 0).
For positive net birth rate gs > 0, there are two growth phases: At the beginning,
the influence of the carrying capacity is small and the population size increases
nearly exponentially. As soon as the number of cells is in the order of magnitude
of the carrying capacity, Ns(t) ≈ K, growth slows down and the number of cells
eventually converges to Nmax. The growth function is shown in Fig. 8 for three
different values of K.
2.2.2 Stochastic emergence of resistant mutants
We assume that the number of resistant mutants is typically orders of magnitude
smaller than the number of sensitive cells. Hence the impact of fluctuations in the
number of resistant cells may not be negligible. Against a background of deter-
ministically growing sensitive cells we treat the growth of the mutant population
within a stochastic framework. We consider the following events:
• Resistant cells reproduce at rate br
(
1−
Ns(t)
K
)
and die at rate dr.
• New resistant mutants arrive through mutation of sensitive cells at rate
µbs
(
1−
Ns(t)
K
)
.
26 resistant mutants in evolving populations
0 10 20
t
0
2500
5000
7500
N
s(
t)
analytic, K = 1000
analytic, K = 5000
analytic, K = 10000
simulation, K = 1000
simulation, K = 5000
simulation, K = 10000
long time limit
Figure 8: Growth dynamics of the sensitive cells for different carrying capacities. The gray
lines indicate the limiting value Nmax. As parameter set we chose bs = 2.5,br =
2.0,ds = dr = 0.5,N0 = 50 and µ = 10−3; the respective values for the carrying
capacities are indicated in the plot.
Under these assumptions, the probability density pk ≡ pk(t) of having k mutants
at time t can be described by the following master equation
dpk
dt
= br(t) · (k− 1) · pk−1 + dr · (k+ 1) · pk+1
− (br(t) + dr) · k · pk + bs(t) · µ ·Ns(t) · (pk−1 − pk), (3)
with the time-dependent growth rates
br(t) = br
(
1−
Ns(t)
K
)
,
bs(t) = bs
(
1−
Ns(t)
K
)
.
Note that the birth rate of both sensitive and resistant cells is coupled to the num-
ber of sensitive cells. In reality, both rates couple to the total number of cells since
both cell types compete for resources. But as explained before, we assume that the
number of sensitive cells is much larger than the number of resistant cells. Thus,
we use Ns(t) ≈ Ntotal(t) to simplify the model.
2.2 semi-stochastic birth-death process with logistic growth 27
We can solve the master equation employing generating function techniques.
The probability generating function is defined as
G(x, t) =
∞∑
k=0
xkpk(t). (4)
Inserting this definition, equation (3) can be written as
∂G(x, t)
∂t
= (br(t) · x− dr) · (x− 1) · ∂xG(x, t)
+ ν(t) · (x− 1) ·G(x, t), (5)
where
ν(t) = µ ·Ns(t) · bs(t) (6)
denotes the time dependent production rate of new mutants. The solution of (5)
is subject to the initial condition
G(x, 0) =
∞∑
k=0
xkpk(t) = x
R0 (7)
with R0 defined as the number of resistant cells at t = 0. We can solve the differ-
ential equation (5) with the method of characteristics and obtain
G(x, t) = (1−Q(x, t))R0 · exp
 t∫
0
ds ν(s) · Q(x, t)ψ(s)
Q(x, t)φ(s) − 1
 , (8)
where we defined the functions
ψ(t) = exp
− t∫
0
ds (br(s) − dr)
 ,
φ(t) =
t∫
0
ds br(s)ψ(s),
Q(x, t) =
1− x
ψ(t) + (1− x)φ(t)
.
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After performing the integration in the definition, we find an easier expression for
ψ(t):
ψ(t) =
(
N0
Ns(t)
)β
egs(β−γ)t
=
(
N0
Nmax
)β
(egst +ω)βe−gst·γ, (9)
where
β =
br
bs
and γ =
gr
gs
=
br − dr
bs(1− µ) − ds
denote the relative birth and growth rate, respectively. Also the integration in the
definition of φ(t) can be carried out which leads to
φ(t) =
brNmax
grω
[
F(0, 1)
N0
−
gr
∆g
F(0, 2)
K
+ egstψ(t)
{
gr
∆g
F(t, 2)
K
−
F(t, 1)
Ns(t)
}]
(10)
with ∆g = gr − gs and
F(t, c) =2F1(1, 1+β− γ, c− γ,−egst/ω),
where 2F1 is the Gauss’ hypergeometric function.
Having derived a closed form solution (8) for the probability generating function
we can now determine the moments of the probability distribution in order to
characterize the number of resistant cells as a function of time. In the following
we assume that we start with no resistant cells at time t = 0, which means R0 = 0.
Mean number of resistant cells
From the probability generating function, the expectation value follows as
R(t) ≡ E(k) =
∞∑
k=0
k · pk(t)
=
∂G(x, t)
∂x
∣∣∣∣
x=1
. (11)
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We find
R(t) =
1
ψ(t)
t∫
0
ds ν(s)ψ(s) (12)
=
bsµNmax
ω
[
1
ψ(t)
{
F(0, 2)
∆g
−
N0
K
F(0, 3)
∆g− gs
}
−egst
{
F(t, 2)
∆g
−
Ns(t)
K
F(t, 3)
∆g− gs
}]
with F(c, t) as defined above. From equation (12) we can compute the time evolu-
tion of the mean,
dR(t)
dt
= ν(t) + (br(t) − dr) · R(t). (13)
It is easy to see that two different processes contribute to the temporal evolution
of the mean: On the one hand, new resistant mutants arrive with rate ν(t). On the
other hand, already existing resistant cells expand with net growth rate br(t) −dr.
Only the second term can become negative; since the birth rate decreases as the
number of sensitive cells approach the carrying capacity, the death rate is even-
tually greater than the birth rate. This means that two different types of growth
are possible depending on how the parameters are chosen: If the net growth rate
multiplied with the number of resistant cells exceeds the production rate at some
point in time, a maximum can exist. If not, the mean increases monotonically. In
the left panel of Fig. 9 the mean number of resistant cells is displayed for different
values for different choices of K.
Variance of the number of resistant cells
From the generating function the variance is given as
V(t) ≡ E(k2) − E(k)2 =
∞∑
k=0
k2 · pk(t) − R(t)2
=
∂2G(x, t)
∂x2
∣∣∣∣
x=1
+
∂G(x, t)
∂x
∣∣∣∣
x=1
−
(
∂G(x, t)
∂x
∣∣∣∣
x=1
)2
, (14)
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Figure 9: Mean and variance of the number of resistant cells as obtained analytically and
by stochastic simulations. We use the same parameter set as defined in Fig. 8.
which leads to
V(t) = R(t)
[
1+
2φ(t)
ψ(t)
]
−
2
ψ(t)2
t∫
0
ds ν(s)ψ(s)φ(s). (15)
As for the mean, we can derive the time evolution of the variance,
dV
dt
= ν(t) + (br(t) + dr)R(t) + 2(br(t) − dr)V(t). (16)
Again, only the last term in the equation becomes negative when the death rate
exceeds the birth rate. In this case, the variance can have a maximum; otherwise
it increases monotonically.
Given a sufficiently large carrying capacity, the variance increases rapidly for
small times as depicted in the right panel of Fig. 9. This is due to the fact that
during the exponential phase the population size is small and an early mutation is
very unlikely to occur. But if it happens, the cells can expand freely until the pop-
ulation size reaches the carrying capacity – so the number of mutants is relatively
high. This means that if the cells can grow in an exponential way sufficiently long,
the variance is dominated for small times by the rare event of an early mutation.
These large fluctuations are the same as observed for the Luria-Delbru¨ck distri-
bution. When the number of sensitive cells reaches its steady state value Nmax,
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Figure 10: Probability of resistance as a function of time (left) and, in the long-time limit,
as a function of population size times mutation rate (right). It becomes clear
that the probability of resistance is mainly determined by µ ·Nmax – other
parameters, as the relative birthrate, only have a minor effect. One can always
increase the population size (or the mutation rate) so that in the steady state
the probability of finding at least one resistant cell is one. We use the same
parameter set as defined in Fig. 8.
the variance decays slowly and eventually saturates. As a result the long-time
fluctuations are much smaller compared to a pure exponential growth law.
Probability of resistance
A patient can only be cured by employing a compound the sensitive cells are sus-
ceptible to provided not a single cell in the tumor carries any resistance mutations.
If, as we assume, cells are either sensitive to treatment or resistant and that this
feature is set at cell birth (which means that cells do not acquire resistance during
their lifetime), the key variable for the prospect of cure is the probability of resis-
tance, which is to say the probability that at least one single resistant cells exists
in the system. We can calculate this probability from the probability generating
function as
pres(t) =1− pk=0(t) = 1−G(0, t)
=1− exp
− t∫
0
ds
ν(s)ψ(s)
φ(t) −φ(s) +ψ(t)
 . (17)
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The time evolution of pres is depicted in the left panel of Fig. 10. As expected,
it increases with time as the population size increases, and, for larger carrying
capacities, converges to higher steady-state values.
Long-time limit
For long times, the number of sensitive cells approaches its maximum value
N¯s ≡ lim
t→∞Ns(t) = Nmax, (18)
which implies that also the birth rates of both cell types converge to
b¯s = lim
t→∞bs(t) = ds1− µ
b¯r =
br
bs
b¯s = β · ds
1− µ
ν¯ = b¯s · µ ·Nmax. (19)
A steady-state solution for the number of mutants can only exist if resistant cells
do not expand exponentially in the long-time limit. To ensure limited growth we
therefore require that the long-time net birth rate is smaller than zero,
b¯r − dr < 0⇒ β < δ,
where δ = drds denotes the relative death rate. If this requirement is met, we can
rewrite the master equation (3) by setting the left hand side to zero and replacing
the time dependent rates by their respective steady state values
0 = ν¯(x− 1)G(x) + (b¯rx− dr)(x− 1)∂xG(x).
This equation is solved by
G(x) =
(
1− βδ
1− x · βδ
) ν¯
b¯r
. (20)
From equation (20) we can now derive the mean number of resistant cells as
R¯ ≡ lim
t→∞〈R(t)〉 = µ1− µNmax(δ−β)−1. (21)
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For the variance we find
V¯ ≡ lim
t→∞V(t) = R¯ ·
(
1−
β
δ
)−1
. (22)
The probability of resistance is thus given by
pres = 1− p0 ≡ 1−G(0) = 1−
(
1−
β
δ
) ν¯
b¯r
= 1−
(
1−
β
δ
) µNmax
(1−µ)β
. (23)
It becomes clear that the steady-state probability of resistance is crucially depen-
dent on the mutation supply rate, which is defined as maximum number of sensitive
cells Nmax times mutation rate µ: No matter how small the mutation rate is, or
how slowly the mutants grow, if the population size is big enough a mutant cell
will exist with probability one. This is shown in Fig. 10 where the steady state
probability of resistance is shown as a function of µ ·Nmax for different choices of
β.
2.2.3 The number of resistant colonies
As outlined in section 2.1.2, the number of resistant colonies is of interest as it can
be measured more easily than the number of resistant cells. By resistant colony we
mean a subpopulation of cells that carry a resistance mutation that is introduced
to the population at one specific mutational event. In genetics, this is usually
referred to as clade. As the PC9 cell line used in the experimental part of this work
grows adherently, cells belonging to one clade are attached next to each other at
the bottom layer of the culture flask. When the population is treated, only the
resistant clades survive and expand – this leads to colony formation where each
colony corresponds to one clade.
It is not straight-forward to formulate a model describing the dynamics of
colonies. The reason is that the microscopic parameters governing birth and death
of colonies need to be defined when switching from a description based on indi-
vidual cells to a coarse-grained description based on colonies. Whereas the birth
rate of the sensitive cells times the mutation rate gives the rate at which new mu-
tations (and thus new colonies) are introduced to the population, describing the
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death process of colonies is much harder. The colony death rate depends on how
big colonies can grow during the exponential phase, and this depends on when
the colony is introduced to the population. This means that colony death is a
barrier crossing problem, where death of a colony is achieved if the colony size
fluctuates to zero. Hence, we do not know the functional form of the colony death
rate. Moreover, all colonies compete against each other for resources. Therefore,
individual colonies are in principle not independent. But as we assume that the
number of mutants is small compared to the number of sensitive cells, the number
of colonies is even smaller. We therefore neglect the interaction between different
colonies and treat them as being independent.
In the following, we assume that colonies die at some time-dependent death
rate dc(t) and that new colonies arise at rate ν(t) as defined in equation (6). We
first show that, independent of the functional form of the colony death rate, the
number of colonies observed in a population follows a Poisson distribution. We
then neglect the time dependence of the colony death rate and use previous results
to calculate its steady-state value.
Consider a large number of sensitive cellsNs(t), growing according to (1). Since
the number of colonies is small, we need to treat it stochastically. The master
equation for the probability pM(t) of having M colonies at time t is given as
∂tpM(t) = ν(t) · pM−1(t) + dc(t)(M+ 1) · pM+1(t) − [ν(t) + dc(t)M] · pM(t),
(24)
with initial condition pM(0) = δM0.
Full distribution
Again, we employ the technique of generating function to solve the master equa-
tion. By introducing G(x, t) =
∞∑
k=0
pk(t)x
k, equation (24) transforms to
∂tG(x, t) = ν(t)(x− 1)G(x, t) − dc(t)(x− 1)∂xG(x, t). (25)
2.2 semi-stochastic birth-death process with logistic growth 35
The solution is given by
G(x, t) = exp (η(t)(x− 1)) (26)
= exp(−η(t)) ·
∞∑
k=0
[x · η(t)]k
k!
,
where we defined
η(t) = exp (−∆(t)) ·
t∫
0
ds ν(s) exp(∆(s))
∆(t) =
t∫
0
ds dc(s)
and plugged in the series representation of the exponential function in the last
step. One can read of that the number of colonies is Poisson distributed
pM(t) = exp(−η(t))
η(t)M
M!
. (27)
This directly implies
〈M(t)〉 = Var(M(t)) = η(t). (28)
In Fig. 11 we compare the histogram of the number of colonies calculated from
simulated data to the values expected from a Poisson distribution. We set the
parameter of the distribution to the mean of the respective data set. One can see
that the the simulated data are very well described by a Poisson distribution for all
times and choices of parameters shown here. The difficulty is that we do not know
the functional form of dc(t), which is why we cannot evaluate the parameter η(t)
of the distribution explicitly.
Mean number of resistant colonies
We can derive the mean number of resistant colonies from (26) by
C(t) ≡
∞∑
M=0
M · pM(t) = ∂G(x, t)
∂x
∣∣∣∣
x=1
= η(t), (29)
36 resistant mutants in evolving populations
0 5 10
M
0.0
0.2
0.4
p
M
t = 2
t = 20
0 10 20
M
0.0
0.1
0.2
0.3
t = 2
t = 20
0 10 20 30
M
0.0
0.1
0.2
t = 2
t = 20
Figure 11: Distribution of the number of resistant colonies as observed in numerical sim-
ulations. As a parameter set we chose, as before, bs = 2.5,br = 2.0,ds = dr =
0.5,N0 = 50 and µ = 10−3. We compare different carrying capacities: K = 103
(left), K = 5 · 103 (middle) and K = 104 (right). Data are shown from two
different time points. The histogram is calculated from the data whereas the
dots denote the values belonging to a Poisson distribution in which we set the
parameter to the mean of the respective observations. One can see that for all
depicted conditions the number of colonies follows an Poisson distribution.
from which we can directly deduce the time evolution of the mean:
dC(t)
dt
= ν(t) − dc(t) ·C(t). (30)
As outlined before, it is not clear how to write down a functional form of the
colony death rate dc(t). At the beginning, the population size is small and only
few colonies are produced due to mutations. Those early colonies can expand
freely since there is not much competition. On the contrary, if the population size
is close to the carrying capacity more colonies are produced per unit time. These
late mutants expand more slowly due to competition and are therefore more prone
to extinction. On the other hand, also the production rate ν(t) of new resistant
colonies varies over time. But it is proportional to Ns(t) which is why it changes
much faster than dc(t). It is therefore plausible to neglect the time dependence of
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Figure 12: Mean number and variance of resistant colonies as obtained by equation (31)
and by numerical simulations. We use the same parameter set as defined in
Fig. 11.
the death rate and approximate it by its steady state value dc(t) = d¯c. Under this
assumption we can write the mean number of colonies as
C(t) =
 t∫
0
ds ν(s) exp(d¯c · s)
 · exp(−d¯c · t)
=
µ
1− µ
[
Ns(t) − e
−d¯c·t
(
N0 +
Nmax
ω
d¯c − ds
d¯c + gs
[
G(0) − G(t)e(gs+d¯c)·t
])]
.
(31)
Here we defined
G(t) =2F1(1, 1+
d¯c
gs
, 2+
d¯c
gs
,−
exp(gst)
ω
),
where 2F1 is the Gauss’ hypergeometric function.
In Fig. 12, we show the mean number of colonies as a function of time for the
parameter set defined above and for three different values K. Although we neglect
the time dependence of the colony death rate, the analytical solution reflects the
temporal evolution reasonably well. We also show the variance of the simulated
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data which, as expected from a Poisson distributed random variable, equals the
mean.
Long time limit.
We can find an analytical expression for the number of colonies in the long time
limit. To calculate the stationary solution of (24) we consider the stationary limits
of all quantities:
pM(t)→ pM
ν(t)→ ν¯ = µ ·Nmax · b¯s
dc(t)→ d¯c
G(x, t)→ G(x).
For this case we find
pM = p0
(
ν¯/d¯c
)M
M!
. (32)
The probability of having zero colonies follows from normalization as
p0 = exp(−
ν¯
d¯c
). (33)
Obviously, the probability of having zero resistant colonies equals the probability
of having zero resistant cells – a quantity we have calculated above:
p0 = 1− pres.
We can use this result to determine the steady-state colony death rate
d¯c = −
ν¯
log(1− pres)
= −dsβ log
(
1−
β
δ
)−1
, (34)
and from this give an analytical expression for the mean number of colonies in the
steady state
C¯ =
∑
k
k · pk = ν¯
d¯c
= −
µ
1− µ
Nmax
β
log
(
1−
β
δ
)
. (35)
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Interestingly, both the relative birth rate and death rate occur in this expression.
This means that it is not enough to know the net growth rates of both cell types to
characterize the number of resistant colonies.
2.3 splitting dynamics
The model investigated so far describes a population of cells whose net growth
stops at some point due to competition for shared resources. In cell culture how-
ever, populations are kept over long times in an exponential growth phase. This
is achieved by regularly extracting a (random) sample of cells and discarding the
rest. In the following we study how this splitting dynamics affects the evolution of
resistance. We first neglect mutations and study how unfit cell types are lost from
the population over time. In a second step, we survey how resistant cells that are
introduced by mutations evolve and can get fixed in the population.
2.3.1 Competition of two types of cells
We investigate how two type of cells growing at different growth rates evolve
under a dynamics that models the splitting procedure. Consider the following
process: We start with a certain number of cells of each type, s ·N0 for type 1
and (1− s) ·N0 for type 2, and the population is allowed to expand for a fixed
time T . At time T , N0 cells are randomly drawn from the population to be further
cultivated, the rest is discarded. Note that this splitting does not take into account
the fitness of the respective type. The two steps are iterated and we are interested
in the question how long it takes until one type is lost from the population. Since,
for the moment, we do not introduce new mutations, one of the two types is
always fixed for long times.
As a minimal model we choose a deterministic picture: Let N1(m) and N2(m)
denote the number of cells of the respective type after the mth exponential expan-
sion. The cells grow with rates g1 and g2, respectively. Given that at the beginning
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of the expansion there exist N(0)1 (m) and N
(0)
2 (m) cells, the cell numbers after the
expansion are given by
N1(m) = N
(0)
1 (m) exp(g1T)
N2(m) = N
(0)
2 (m) exp(g2T).
The probability of sampling type 1 follows as
p(m) =
N1(m)
N1(m) +N2(m)
(36)
As binomial sampling leaves the expected fraction of type one cells unchanged,
the initial number is connected to the sampling probability after the (m − 1)st
expansion as
N
(0)
1 (m) = N0p(m− 1)
N
(0)
2 (m) = N0[1− p(m− 1)].
With this, we find a recursive relation for the sampling probability,
p(m) =
1
1+
1−p(m−1)
p(m−1) exp(−∆gT)
, (37)
which has to be solved subject to the initial condition
p(0) = s.
The solution is given by
p(m) =
1
1+ 1−ss exp(−m∆gT)
, (38)
as can be easily shown by induction:
As a base case, we considerm = 0. From equation (38), the correct initial condition
p(0) = s follows directly. So if p(m) holds, we need to show that
p(m+ 1) =
1
1+ 1−ss exp(−(m+ 1)∆gT)
.
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Figure 13: (left) Mean fraction of type 1 cells under splitting dynamics with two compet-
ing types for s = 0.5, T = 4, ∆g = −0.02 (red) and ∆g = −0.18 (yellow). The
dots indicate numerical simulation and the lines are given by (38). (right) Time
(in number of passages) until unfit type is lost from the population, where lost
means the passage mL where the a fraction of the fitter type makes up 0.99%
of the population.
Starting from (37), we find
p(m+ 1) =
[
1+
1− p(m)
p(m)
exp(−∆gT)
]−1
=
1+ 1− 11+ 1−ss exp(−m∆gT)
1
1+ 1−ss exp(−m∆gT)
exp(−∆gT)
−1
=
1
1+ 1−ss exp(−(m+ 1)∆gT)
,
where, in the second step, we used the induction assumption.
For large m, the probability p(m) will, depending on the sign of ∆g, always
converge to either 0 or 1. This is to be expected: As we did not include mutations,
cells cannot change their type and the faster growing type will take over the pop-
ulation. The time (in number of passages) until fixation depends on the fitness
difference, and occurs faster the greater the fitness difference is (see Fig. 13).
2.3.2 Splitting under Luria-Delbru¨ck dynamics
Next we consider mutations. Apart from dividing, sensitive cells can mutate at
rate µ per generation. The dynamics of an exponentially expanding population
in which sensitive individuals can mutate to become resistant has originally been
investigated by Luria and Delbru¨ck who considered growth of both cell types to
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be deterministic; on top of the expansion process, mutations occur stochastically.
We adapt a more general formulation, originally given by Lea and Coulson [51],
who consider the growth of the mutant cells as a stochastic birth process. Let
pR ≡ pR(t) denote the probability of having R mutants at time t. We assume that
sensitive cells grow at rate gS, resistant cells grow at rate gR and sensitive cells
mutate to resistant cells at rate µ · gS. Then the dynamics of the mutant cells is
described by the following master equation:
∂tpR = gR[(R− 1)pR−1 − R · pR] + µ · S(t) · [pR−1 − pR], (39)
where S(t) = N0 exp(g1t). As we are interested in the expectation value of the
resistant mutants, we multiply both sides of the equation with R and sum over all
R. We find
∂t〈R〉 = g2〈R〉+ µS(t), (40)
where 〈R〉 ≡
∞∑
R=0
R · pR(t). This differential equation can easily be solved subject
to the initial condition pR(t = 0) = δR,0 and we find
〈R〉 = N0 µ
∆g
[1− exp(−∆gt)] · exp(gSt), (41)
where ∆g = gS − gR.
As a minimal model describing the splitting dynamics, we again work on the
level of expectation values. For every expansion of length T , we have to take into
account two contributions: First, already existing resistant mutants will expand.
Second, sensitive cells introduce new resistant cells through mutation. Using equa-
tion (41), the mean number of resistant mutants after the mth expansion, which
we call RT (m), is given by
RT (m) = R0(m) · exp(gRT)︸ ︷︷ ︸
expansion of existing mutants
+(N0 − R0(m)) · x · exp(gST)︸ ︷︷ ︸
introduction of new mutants
= R0(m)[exp(g2T) − x exp(g1T)] + RT (1)
= N0 · pLD(m− 1)[exp(g2T) − x exp(g1T)] + RT (1), (42)
where we introduced x ≡ x(∆g,µ) = µ∆g [1− exp(−∆gT)]. Furthermore, R0(m) de-
notes the expectation value of resistant cells at the begin of the mth expansion and
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pLD(m) is the mean sampling probability after the mth expansion. Analogously,
the expected number of sensitive cells is given by
S(m) = (N0 − R0(m)) exp(gsT)
= N0(1− p
LD(m− 1)) exp(gsT).
The two equations define a recursive relation for the sampling probability,
pLD(m) =
RT (m)
RT (m) + S(m)
=
pLD(m− 1)[y− x] + x
pLD(m− 1)[y− x− 1] + 1+ x
, (43)
where we used y = exp(−∆gT) as a shorthand. Equation (43) is solved by
pLD(m) =
1− ym
∆g
µ + 1− y
m−1
, (44)
which again can be easily shown by induction. As we assume that resistant cells
grow slower than sensitive cells, ∆g > 0 and thus y < 1. So, for large m, equation
(44) converges to
p¯LD ≡ lim
m→∞pLD(m) =
(
∆g
µ
+ 1
)−1
, (45)
which yields, for finite µ, the limits
p¯LD =
1 for ∆g→ 00 for ∆g→∞ . (46)
The two limits describe extreme situations: If both cell types grow at the same
rate, in the long-time limit the mutants will always take over the population. This
is due to the fact that we did not include back mutations – resistant cells cannot
produce sensitive cells. So if the fitness difference is small, resistant mutants will
accumulate. On the other hand, if the fitness difference is large, resistant mutants,
even if they are introduced to the population, tend to be lost from the population
due to their fitness disadvantage. Hence mutation and selection can balance so
that resistance mutants occur at some fixed sampling probability in the steady
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Figure 14: (left) Mean fraction of resistant cells under LD splitting dynamics with two
competing types for s = 0.5, T = 2.5, µ = 0.0015, ∆g = 0.075 (red) and ∆g = 0.6
(yellow). The dots indicate numerical simulation and the lines are given by
(44). (right) Steady state fraction of resistant cells as a function of growth rate
as given by equation (45).
state. This is also shown in Fig. 14, where we simulated the splitting dynamics
with mutation for two different choices of ∆g.
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3.1 introduction
3.1.1 Can targeted therapy be curative?
When the first small molecules targeting molecular cancer abnormalities were
approved for clinical use, scientists and clinicians were enthusiastic about the
prospects of cure under targeted therapy. If a targeted drug (for example a kinase
inhibitor) is delivered to a patient with the right mutational profile, the response is
often dramatic and the tumor vanishes within few weeks – often with manageable
side effects. It seemed as if the remaining task in drug discovery was more of an
engineering than of a conceptual problem: Finding a molecule against each possi-
ble driver mutation would be enough to cure cancer. Unfortunately, today it is a
well known fact that for solid tumors the efficacy of targeted therapy is limited by
the occurrence of resistance in very nearly every case1. Within few months, the tu-
mors grow back, with changed mutational profile so that the tumor grows despite
continued therapy. At first glance, this seems surprising: How can a tumor be so
smart to evolve in exactly the right way to overcome a specific targeted drug? But
when looking at the numbers governing tumor evolution, it becomes clear why
resistance to targeted therapy is so prevalent.
Each tumor is initiated by a single mutated and quickly dividing cell. Due
to unavoidable errors in DNA replication, at each cell division there is a small
but non-zero probability for some mutation to occur. Generally, mutation rates
1 There is one single example in which targeted therapy also works long-time, namely in chronic
myeloid leukemia (CML) that can be treated with Imatinib. CML is driven by a gene fusion of the
two genes BCR and ABL, which leads to an unusually short chromosome causing uncontrolled cell
proliferation. Before the advent of targeted therapies, people inevitably died from CML within 4− 6
years. Imatinib is a tyrosine kinase inhibitor specifically targeting the BCR-ABL fusion gene, and
has shown to be impressively successful in patients: People who experienced a two year remission
under Imatinib do not have a decreased life expectancy as compared to the general population [59].
45
46 iterative exhaustion of resistance mechanisms to targeted therapy
are estimated to be in the order of magnitude of 10−8 [60] per nucleotide and
cell division 2. So a single cell is very unlikely to acquire a specific mutation in
one division event. However, in a tumor the population size increases over time
and the probability that a mutation in a given position arises in some cell rises
concomitantly. While most mutations do not affect cell function, very specific
mutations can confer resistance to targeted therapy. Thus the specificity of targeted
therapy is both a blessing and a curse.
One gram (or approximately 1 cm3) of tumor tissue contains not less than 108
individual cells [61]. Even though tumors as small as 4mm can be theoretically de-
tected in a CT scan, most patients are diagnosed with cancer in much later stages.
For non-small cell lung cancers (NSCLC) for instance, a study on patients that have
undergone surgery with curative intent reported that in their cohort less than 20%
of all tumors were smaller than 2 cm (corresponding to about 108 cells), and more
than 55% had a diameter of 3 cm (corresponding to 109) or more [62]. As patients
with very large or metastasized tumors were excluded from the study, it is likely
that lung tumors are often even bigger. This example shows that tumors at diag-
nosis usually consist of 108 − 109 cells, and that, on average, µN ≈ 1− 10 mutants
with each possible point mutation are created per generation. As a result, at the
time treatment begins on a macroscopically-sized tumor, the population inevitably
contains cells carrying a resistance mutation if a single nucleotide resistance mu-
tation exists. These resistant cells expand under treatment while non-resistant
cells are killed. Eventually, resistant cells repopulate the tumor, leading to the
acquired resistance phenotype. Typically, there are different genetic alterations
(point mutations, gene amplifications and deletions, ...) which confer resistance
to a given targeted therapy. For example, tumors driven by an activating muta-
tion in epidermal growth factor receptor (EGFR) respond to the EGFR tyrosine
kinase inhibitor Erlotinib. Mutations conferring resistance to Erlotinib treatment
include the well-studied gatekeeper mutation EGFR T790M [63, 64], but also point
mutations in BRAF and PIK3CA, as well as copy number alterations in MET and
HER2. A similar picture holds for targeted therapies acting on other mechanisms,
like ALK-rearranged tumors where several ALK mutations as well as increased
EGFR signaling and KIT amplification have been identified as possible resistance
mechanisms [41]. In a population of cancer cells, the different resistance muta-
2 This rate was measured for normal, non-cancerous human dermal fibroblasts. Usually, cancers are
genetically instable, which means that the mutation rate is elevated and that this estimate should be
understood as a lower bound.
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Figure 15: A Muller plot schematically shows the population dynamics of different geno-
types with time running along the x-axis. Parental cancer cells, which respond
to targeted therapy are indicated in gray. Different resistant mutants, indicated
in red, yellow, green, and blue, appear through random mutations at different
times and disappear again from the population as they typically grow slower
than the parental cell type. If parental tumor cells are eradicated at some point
in time due to targeted therapy, the remaining resistant cells expand and com-
pete with each other.
tions arise independently, so mutant cells with different resistance mechanisms
can co-exist in a large population of tumor cells. The different mechanisms then
compete with each other once non-resistant cells have been eliminated by therapy,
see Fig. 15. These considerations indicate that targeted mono-therapy can only be
curative when applied to a tumor that does not contain any resistant mutants – a
scenario that is very unlikely for macroscopically detectable tumors, see Fig. 16.
Instead, if targeted therapy is to achieve a long-term remission, it needs to address
all resistance mechanisms present in a population of cancer cells.
In the following, we use artificial evolution to study the problem of resistance
to targeted therapy arising from pre-existing mutants. We iteratively isolate differ-
ent resistance mechanisms existing in a large cell culture by amplifying resistant
mutants. As a proof of principle, we apply our method to PC9 cells, a human
adenocarcinoma-derived cell line with an activating mutation in the growth factor
receptor EGFR. To analyze rare mutations, we culture large cell populations of size
5× 108 cells. This number is far beyond the small pools containing thousands of
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Figure 16: We show the probability of having at least one resistant mutant in the popula-
tion as a function of tumor size for different mutation rates (solid line µ = 10−9,
dashed line µ = 10−8 and dotted line µ = 10−7; roughly corresponding to one,
ten or hundred resistance mechanisms mediated by point mutations occurring
at the background point mutation rate; or to the background mutation rate, a
tenfold or a hundredfold increased mutation rate, for instance due to genetic
instability). The plot is based on equation (17) in the limit β → 0. To map the
population size Nmax to tumor size we assume a spherical tumor and a cell
density of 108 cells per cm3. Different characteristic tumor sizes and stages are
indicated along the x-axis. The plot shows that, if the mutation rate exceeds
10−7, a detectable tumor inevitably contains therapy resistant mutants.
cells used previously [65] and is of the order of magnitude of detectable tumors.
By characterizing the respective resistant lines, we show that several distinct resis-
tance mechanisms exist simultaneously in the cell population prior to treatment
and that their fitness determines which one emerges under treatment. Our key
finding is that, for PC9 cells, a set of four compounds is sufficient to suppress all
the resistance mechanisms we identified in such a population, and this holds even
when the mutation rate is enhanced through a chemical mutagen. Our findings ex-
plain why, for solid tumors, long-term control of the disease with targeted therapy
has proven elusive so far and point to a treatment strategy differing from current
clinical practice: Instead of keeping the treatment fixed until a relapse occurs, tu-
mor evolution needs to be anticipated by targeting a broad spectrum of possible
resistance mechanisms as early as possible.
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Figure 17: Our experimental scheme aims to isolate the fastest growing resistance mech-
anism by treating a large population of cells, most of which are susceptible to
targeted therapy (gray points). The fastest growing resistant mutant (yellow)
takes over the population and is screened against a panel of compounds cov-
ering a wide range of resistance mechanisms. In the next step, we again treat
a large population, but with the original, first-line compound, as well as the
compound active against the first resistance mechanism (yellow cells). This
leaves a second resistance mechanism, which we isolate for screening and anal-
ysis. Each step generates a new resistance mechanism, as well as a compound
acting on that mechanism.
3.1.2 Experimental protocol
Many resistance mechanisms can be targeted by specific drugs. If all resistance
mechanisms present in a cancer cell population were known, and if we knew how
to selectively target these resistance mechanisms, we could eliminate not only the
bulk of therapy-susceptible cancer cells, but also eradicate the cells carrying resis-
tance mutations. Key obstacle is that it may not be possible to identify resistant
mutants by sequencing a large population of cells, as the frequency of mutants
may be far below the detection threshold. To address this problem, we devel-
oped an experimental protocol to iteratively amplify all resistance mechanisms in
a population of given size.
The idea is the following: On the one hand, we take a well defined model
system driven by a known mutation that makes a cell cancerous (a so-called driver
mutation). In the following we call this parental cell line P. On the other hand,
we define a drug panel that covers drugs acting on that driver mutation and on
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compound targets compound targets
Erlotinib EGFR AZ628 RAF
Osimertinib EGFR (T790M) Imatinib c-ABl/c-KIT/PDGFR
Lapatinib EGFR/HER2 Sorafenib RAF-1/B-RAF/VEGFR-2
Tepotinib c-MET Sunitinib VEGFR-2/PDGFRβ
Crizotinib c-MET/ALK Regorafinib VEGFR/PDGFRβ/KIT/RET/RAF-1
Trametinib MEK Dactolisib PI3K/mTOR
Dabrafenib BRAF (V600) Dasatinib ABL/SRC/c-KIT
Apitolisib PI3K/mTOR SCH77298 ERK
BGJ398 FGFR
Table 1: Compounds and respective targets for the drug panel as employed in our exper-
imental protocol. The drugs were chosen such that they cover all known and
putative resistance mechanisms to targeted EGFR inhibition.
all known resistance mechanisms to this kind of treatment. In an initial round,
we determine which drug works best on the P cell line. We call this compound
drug A. We then iterate the following steps: We expand P up to a population
size of 5× 108 cells. We treat with drug A until resistant cells emerge. Several
resistance mechanisms will survive the treatment, but the fittest one will usually
take over the population. We call this new resistant cell line R1. We screen R1
against the drug panel to identify a drug that eliminates R1, which we call drug
B. We then take one step back and again expand P to obtain a population size of
5× 108 cells. But now we treat with both drug A and drug B: Drug A will kill the
parental type, whereas drug B works against R1 such that the next fittest mutant
type can take over the population (cell line R2). We screen R2 against the drug
panel to determine the most effective compound for this cell type. For a sketch
of the protocol see Fig. 17. These steps are iterated until a) we derive a cell line
that is resistant against all drugs in our panel or b) we cannot derive a cell line
resistant to some drug combination. Both possible outcomes of course have severe
implications for the prospects of cure under targeted therapy.
To realize tumor-sized populations of 5× 108 cells we use hyperflasks, special
culture bottles that consist of ten intermediate layers on which cells can grow. The
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crucial advantage is that these bottles are much more time and space effective
than standard culture bottles: The whole bottle is filled with medium only once,
whereas standard culture flask would require ten individual handling steps to
reach the same population size. This cuts down the time that is used for each
medium change nearly by a factor of ten. Moreover the hyperflask is only approx-
imately twice as large as ordinary bottles, which saves valuable incubator space.
An important disadvantage is that only the top and the bottom layer can be ob-
served with a microscope, and even this is hard if the bottle is completely filled
with cells as the density becomes too high for enough light to pass through all the
layers. To circumvent this limitation, we transfer the surviving population in each
iteration after two weeks of treatment to an ordinary culture flask with growth
area 75 cm2 (so called T75 growth bottle). This enables us to further monitor the
population growth and to determine if cells are actually expanding under treat-
ment. As soon as the population size is large enough, a sample of cells is frozen
as a backup. The next time the population size reaches confluence, a sample is
taken for DNA sequencing. Only after those two steps, the cell line is screened
against the drug panel.
As a model system, we use PC9 cells, a human adenocarcinoma-derived NSCLC
cell line driven by an EGFR mutation that has been studied extensively. PC9
cells are sensitive to the first generation EGFR tyrosine kinase inhibitor Erlotinib
with a GI50 (concentration at which cell viability drops at 50% of control viability
without treatment) of approximately 30nM. When treated with Erlotinib, PC9 cells
usually develop resistance via a secondary mutation in EGFR, the so called T790M
gatekeeper mutation. Mutants carrying T790M can in turn be targeted with third
generation EGFR inhibitors such as Osimertinib. The advantage of such a well
established model system is that we already know what to expect for the first
experimental iteration, which offers a possibility to check if our method works
properly.
As Erlotinib has been approved for clinical use already in 2004, many resistance
mechanisms have been described since then (for a review see [41]). Based on that,
our drug panel covers all known and putative resistance mechanisms to EGFR
inhibition. The full panel including drug targets is shown in Table 1.
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Tepotinib 
Crizotinib 
Dasatinib 
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Apitolisib 
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Lapatinib 
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Figure 18: Drug responses of different compounds against the parental and the four dif-
ferent resistant cell lines. The main drug targets are annotated in gray. As a
measure for sensitivity we use the area under the curve (AuC). High suscep-
tibility, corresponding to a low AuC, is indicated in red. The responses are
always measured as the formerly identified compounds plus the drug given in
the table (meaning P is cultivated in pure growth medium plus the respective
drug, R1 in Erlotinib plus the respective drug, R2 in Erlotinib, Osimertinib plus
the respective drug, etc.). The resistance of successive cell lines to compounds
previous lines are still susceptible to leads to the diagonal structure at the top
right of the compound-susceptibility matrix.
3.2 results
3.2.1 Different resistance mechanisms pre-exist in a large cell population andrespond to different compounds
Based on the above experimental protocol, we derived four different cell lines
resistant to Erlotinib. R1 exhibits the well-known EGFR mutation T790M, and re-
sponds to the third-generation EGFR inhibitor Osimertinib. R2 exhibits a point
mutation in NRAS, a gene downstream of EGFR in the MAPK pathway. This mu-
tation, NRAS Q61R, is known to confer sensitivity to MEK inhibition. Indeed, R2
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responds most strongly to the joint inhibition of EGFR and MEK. In R3, we found
an up-regulation of the growth factor receptor MET (which can at least partly
substitute the EGFR signal) as well as a focal amplification and up-regulation of
the corresponding ligand HGF. In accordance with this observation, R3 responds
most strongly to the joint inhibition of EGFR, MEK and MET. In R4 we did not
find an obvious genetic alteration responsible for therapy resistance, but found R4
to be sensitive to Pi3K/mTOR inhibition. The responses of the full drug panel
against the parental and the four different resistant cell lines R1-R4 is depicted in
Fig. 18. Importantly, all cell lines respond specifically to compounds acting on
a particular target instead of showing a broad response, which indicates that the
drug combinations of three or more compounds are not generally toxic.
To determine the fitness of the different lines, we measured their growth rates,
see Fig. 19. We find that the resistant cell lines do not only differ in drug sensitivity
but also grow at different rates: R1 grows at 96% percent of the rate of the parental
PC9 cells, R2 at 91%, R3 at 74% and R4 at 79% (gP = 0.82± 0.02, gR1 = 0.79± 0.01,
gR2 = 0.75 ± 0.01, gR3 = 0.61 ± 0.04 and gR4 = 0.65 ± 0.02 cell divisions per
day). Thus, the resistant cell lines grow more slowly than wild type cells, as is
to be expected: If a resistance mutation offering a fitness advantage existed in the
population, it would have taken over the population and would have become the
wild type. Also, the fast-growing resistance mechanisms tend to be isolated first,
as to be expected from our iterative scheme.
To test if the different cell lines maintain their resistance without selection pres-
sure, we cultivated the four resistant lines without treatment and repeatedly mea-
sured their resistance to therapy. As shown in Fig. 20, no significant reduction
in resistance was found after 14 weeks, which implies stable genetic or epigenetic
resistance mechanisms.
3.2.2 Different resistance mechanisms show distinct disruptions in signalingpathways
To investigate if the sensitivity measurements are compatible with cell signaling,
we examined the protein levels of the parental and the resistant cell lines. To
this end, we performed Western blots of the most important components of the
EGFR signaling pathway. As seen in Fig. 21, the delivery of Erlotinib shuts down
the phosphorylated EGFR (pEGFR) and also the downstream pERK signal. Con-
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Figure 19: The different resistant cell lines differ in their growth rate, as seen by tracking
their population growth over a four-day period. As expected, fast-growing
resistant types are isolated first. The growth rate of R4 was measured by Carina
Lorenz (lab of Martin Sos).
versely, in R1 the delivery of Erlotinib does not affect the EGFR or any downstream
signal. This is to be expected: Erlotinib binds in an ATP-competitive manner to the
EGFR kinase domain. The T790M mutation increases the binding affinity for ATP
by an order of magnitude, which weakens the binding affinity for ATP-competitive
agents such as Erlotinib [66]. This is why the inhibitor cannot effectively bind any-
more and explains why the compound does not have any effect. Osimertinib in
turn has a different mode of action and binds covalently, thus inhibiting EGFR
even in the presence of high ATP concentrations [67]. This is why it overcomes
the T790M mutation and shuts down the pEGFR and the respective downstream
signal compatible with the sensitivity we measured in the viability assay. In R2,
the pEGFR signal is eliminated by Erlotinib and Osimertinib, but, importantly, the
downstream pERK signal remains. This means that there has to be some activa-
tion upstream of ERK that substitutes the pEGFR signal. This observation can
be explained by the NRAS Q61R mutation that we found in R2. As expected,
the additional delivery of Trametinib silences the downstream signal and restores
sensitivity to EGFR inhibition.
In R3 we found a focal HGF amplification. It has been shown that a high con-
centration of the growth factor HGF in the culture medium makes cells resistant
to EGFR inhibition [68]. Indeed, if we add HGF to normal growth medium, the
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Figure 20: Stability of the resistant lines after compound withdrawal. The dashed line
gives the AuC as measured in parental PC9 cells. The dots indicate individual
measurements, the lines gives trend lines. After 14 weeks, none of the cell lines
reaches the sensitivity level of the parental line which indicates stable genetic
or epigenetic resistance mechanisms. We further show the AuC as measured
for cells derived from drug tolerant cells persisting despite therapy (exDTPs,
see Section 3.2.4) after compound withdrawal. Once the culture is large enough
for analysis, it exhibits the same sensitivity as the parental line which implies
a reversible persister state instead of a stable mechanism.
GI50 of the parental cells is increased by orders of magnitude, see Fig. 22, left
panel. To measure the HGF concentration in the growth media of the different
cell lines, we performed an HGF enzyme-linked immunosorbent assay (ELISA).
For this method, samples from the growth medium of the cell line that is to be
examined are transferred to a plate that is coated with antibodies that specifi-
cally bind to the target of interest (in our case HGF). After several incubation and
washing steps, a substrate solution is added which develops color in proportion
to the amount of bound HGF. The color intensity can be measured to quantify
the amount of HGF that was secreted into the growth medium. Indeed, we find
highly increased HGF levels in R3 as compared to the other cell lines. HGF is the
ligand of MET, a growth factor receptor that can – among other signaling trans-
duction pathways – activate the MAPK pathway. So the MET signal induced by
the increased HGF amount offers a bypass-track for the missing EGFR signal and
explains why R3 is resistant to EGFR inhibition.
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Figure 21: Protein levels of some important components of the MAPK pathway. Black
bands show the presence of a specific protein, either the total amount (for
instance tEGFR) or the phosphorylated version (for instance pEGFR). To en-
sure even protein loading in all samples, we further blotted the housekeeping
protein HSP90 as a control. In the parental line P, the delivery of Erlotinib si-
lences EGFR and the downstream signal in ERK. In R1, Erlotinib in turn does
not change the EGFR signal and only the additional delivery of Osimertinib
shuts down the pathway. In accordance with the observed NRAS mutation in
R2, the EGFR inhibitors cancel the EGFR signal, but the ERK signal further
downstream in the signaling pathway remains. Only the additional delivery of
the MEK inhibitor Trametinib restores EGFR sensitivity. The western blot was
performed by Carina Lorenz (lab of Martin Sos).
In R4 we could not identify a genetic alteration explaining the resistance. But
as shown in Fig. 18, R4 reacts most strongly to the dual PI3K/mTOR inhibitor
Dactolisib. The PI3K/AKT/mTOR pathway can have, when activated, multiple ef-
fects on cells, such as enhancing cell survival, stimulating proliferation and growth.
The activation of this pathway has been reported in cancers in various contexts. To
further determine which part of the pathway needs to be inhibited, we screened
R4 against an extended panel of compounds, see Fig. 23, left panel. It becomes
obvious that R4 is sensitive to mTOR or PI3K/mTOR dual inhibition, but not to
AKT inhibition. We further checked protein levels to investigate cell signaling.
The delivery of Dactolisib or Apitolisib does not affect the pERK signal, but shuts
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Figure 22: (left) The addition of the growth factor HGF to the culture medium make PC9
cells resistant to EGFR inhibition: Whereas the GI50 is usually less than 100nM,
the delivery of 50ng/ml HGF makes the cells survive concentrations of several
µM. (right) By performing an ELISA specific to HGF we measure increased
HGF levels in the growth medium of the R3 cell line confirming the HGF
amplification as the relevant resistance mechanism.
down p4EBP1 (a downstream target of mTOR) and pAKT. This indicates that the
necessary survival signal in R4 is pAKT rather than pERK as in the parental cells.
3.2.3 No further resistance mechanisms arise under a combination of compoundstargeting R1-R4
One interesting finding in the drug sensitivity matrix shown in Fig. 18 is that
both R3 and R4 respond to the same drug, namely to the relatively broad inhibitor
Dasatinib. This is surprising: even if we could not find a detailed explanation of
the resistance mechanism in R4, it definitely differs from the HGF amplification
we found in R3 (or any other MET related mechanism that would be targeted by
the MET inhibitor Tepotinib). An obvious question to ask is if this is a coincidence
or if there is something more general, meaning for instance that the combination
Erlotinib, Osimertinib, Trametinib and Dasatinib (EOTD) is broad enough to tar-
get all possible resistance mechanisms in PC9 cells. To approach this question,
we tried, according to our protocol, to derive cells resistant to the four drug com-
bination EOTD. We failed to find any cells growing under this combination in
three independent runs of the experiment. To exclude the possibility that some
growing cells survived treatment but were lost in the necessary washing and cen-
trifugation steps when transferring the surviving population from the hyperflask
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Figure 23: PI3K/mTOR activation drives resistance in R4. (left) Response to the extended
drug panel targeting several parts of the PI3K/AKT/mTOR pathway. The
parental cells are only treated with the indicated compounds, whereas in R4
we measure the additional effect to the standard R4 selection medium con-
taining Erlotinib, Osimertinib, Trametinib and Tepotinib (EOTT). We find that
R4 responds to mTOR and PI3K/mTOR dual inhibition, but not to AKT in-
hibition. (right) Western Blot of R4 cells showing some components of the
PI3K/AKT/mTOR pathway. Again, the housekeeping gene HSP90 serves as
a control to secure even protein loading and the treatment needs to be under-
stood as EOTT plus the indicated compound. The delivery of Dactolisib or
Apitolisib does not affect the pERK signal, but shuts down p4EBP1 (a down-
stream target of mTOR) and pAKT. This indicates that the necessary survival
signal in R4 is pAKT rather than pERK as in the parental cells. The western
blot was performed by Johannes Bra¨gelmann (lab of Martin Sos).
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Figure 24: Culture flasks containing 5 × 107 cells are treated with ENU, such that the
mutation rate is elevated by a factor of ten. After three weeks of treatment
start, hundreds of small colonies (visible as gray spots) grow under Erlotinib
mono-therapy (left). Under EOTD, not a single colony is observed (right).
(with a large growth area which is not completely observable) to the T75 culture
flask (with a smaller growth area which is completely observable), we treated a
population of 5 × 107 cells in a T175 bottle with a single dose of the chemical
mutagen N-ethyl-N-nitrosourea (ENU) which enhances the mutation rate approx-
imately tenfold [60]. Whereas in flasks treated only with Erlotinib hundreds of
resistant colonies developed after two weeks of treatment, we did not observe a
single colony under EOTD, see Fig. 24. Interestingly, the culture flasks were not
completely empty: Even after several weeks of treatment, we could – with a mi-
croscope – find isolated cells (10− 100 cells per T175 bottle). Importantly, those
cells did not expand as they did not form small colonies over time. We conclude
that, even if we could not identify further resistance mechanisms, the problem of
resistance to EGFR inhibition in PC9 cells has yet another dimension: Cells that
neither die nor grow under treatment.
3.2.4 Sleeper cells can survive the combination treatment
In order to probe if all proliferating cells from the original population had been
eradicated, we stopped the EOTD treatment after seven weeks. Two weeks after
the treatment had stopped, we observed the growth of a small number of colonies,
obviously stemming from the few cells that persisted under EOTD treatment. In-
terestingly, these colonies responded to Erlotinib mono-therapy. To check if this
behavior was reproducible, we treated a bottle of PC9 cells for one week with
EOTD, stopped the treatment and waited until we had enough cells to screen
them against Erlotinib. In several independent runs of the experiment, we could
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Figure 25: To quantify the population fraction that can survive under different compound
combinations, we treated full bottles of parental PC9 cells with the indicated
drugs. After four days, we counted the number of cells and normalized every-
thing to the number of sleepers that survived under Erlotinib mono-therapy
(Erlotinib DTPs). Here, we show the result of three independent runs of the
experiment. The gray bars indicate the mean, the error bars the standard devi-
ation. We did not observe a difference when treating with EO as compared to
Erlotinib only. But when adding Trametinib, the surviving fraction drops by a
factor of two, and when adding Dasatinib, even by a factor of ten.
always derive proliferating cells and did not observe a difference in Erlotinib sen-
sitivity between the cells that emerged from sleeper cells and parental cells (see
the gray triangles in Fig. 20). We concluded that the surviving cells were not truly
resistant to the treatment, but a fraction of the population was in a drug tolerant
persister state that was reversed after treatment had stopped.
The phenomenon of persisting cells has already been described in the context of
Erlotinib resistance in PC9 cells: a part of the population, there called drug-tolerant
persisters (DTPs), survives treatment and can eventually lead to the emergence of
resistance [65, 69]. We measured that about 20% of the population survived four
days of Erlotinib treatment. But under EOTD, we observed far fewer cells surviv-
ing treatment. To quantify the effect, we treated full bottles of parental cells with
Erlotinib (E), Erlotinib and Osimertinib (EO), Erlotinib, Osimertinib and Trame-
tinib (EOT) and EOTD. As shown in Fig. 25, we did not observe any difference
between E and EO treatment. But when adding Trametinib, the surviving frac-
tion drops by a factor of two, and when adding Dasatinib, even by a factor of
ten. These observation could indicate that there exists a spectrum of different per-
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Figure 26: Cluster analysis of gene expression of sleeper cells (here called DTPs), cells that
emerged from sleepers and parental cells. Blue colors indicate high similarity,
red colors high differences. One can observe that two distinct clusters: One
containing all sleepers and the other one containing both parental cells and
cells that emerged from sleepers indicating that there are no major differences
between the two types. This means that the sleeper state might be completely
reversible. We also indicate the date at which we extracted RNA, to see if there
are any batch effects, but we do not observe any dependence on the extraction
date. The figure was created by Johannes Bra¨gelmann (lab of Martin Sos).
sistence mechanisms (similar to the spectrum of co-existing resistance mechanism)
that allows cells to survive under different compound combinations. Further work
is needed to confirm this result.
To investigate the gene expression of the sleeper cells, we treated parental cells
for one week with EOTD and extracted RNA from the surviving cells. As shown
in Fig. 26, the expression of sleepers differs from the one of parental cell, but
parental and cells that woke from the sleeper state fall into one cluster. This
indicates that the persister state is completely reversible and probably not caused
by genetic mutations. Previous work showed persister cells to be dependent on
the lipid hydroperoxidase GPX4 for survival, thus identifying GPX4 as a possible
target to inhibit [70]. While we observed a higher GPX4 expression in sleeper cells
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as compared to parental cells, we did not find an increased sensitivity of sleepers
to the GPX4 inhibitor RSL3.
Finally, we studied how the sleeper cells wake up from the persister state. We
came up with two possible hypothesis: a) It could be an active process, meaning
that sleepers stay in their drug tolerant state as long as treatment is maintained.
Once the compounds are removed from the medium, cells sense the changed con-
ditions and actively switch back to the proliferating state. This hypothesis would
imply that the number of surviving cells does not depend on the treatment time.
b) It could be a stochastic process, meaning that sleepers leave the persister state
with certain probability all the time, independent of the treatment status. If the
treatment is still on, cells immediately die. If the treatment is off, they can ex-
pand. This hypothesis implies that the number of surviving cells depends on the
treatment time: the longer the population is treated, the lower the number of sur-
viving cells. To test the two possibilities, we treated full bottles of parental cells
with EOTD for different times (2, 3, 5 and 7 weeks). After the treatment stopped,
we let surviving cells expand for 2.5 weeks and counted the emerging colonies.
To simplify the quantification, we stained with crystal violet, two sample pictures
are shown in Fig. 27. As depicted in Fig. 28, we observe an exponential decay in
the number of colonies, falsifying the hypothesis that cells wake up in response to
treatment stop.
3.3 discussion
Currently, the standard treatment for cancer patients who respond to some tar-
geted therapy is to continue this treatment until a relapse occurs. This strategy
implies that one waits for a macroscopically sized tumor to grow despite treat-
ment before changing the medication. In most cases, the time until a relapse is
roughly a year: A study investigating Erlotinib as first-line therapy3 compared
to classical chemotherapy in EGFR driven NSCLC found a median progression
free survival (PFS, the time during the treatment in which the tumor does not get
bigger) of 9.7 months for Erlotinib versus 5.2 weeks for chemotherapy [71]. If a
patient is lucky, the relapse is driven by a known resistance mechanism like the
3 The term first-line therapy is defined as the first treatment that is given for a disease. If at some point
the medication is changed because the initial treatment stopped working or the patient suffers from
unbearable side effects, the new treatment is called second-line therapy.
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Figure 27: To study the dynamics of how cells exit the persister state, we treated full
bottles of parental PC9 cells with EOTD and varied the treatment time. Each
violet spot corresponds to one colony that was stained for counting. On the
left, the population was treated for two weeks before cells could expand for
two and a half weeks. On the right, the population as treated for five weeks
and again cells could expand for two and a half week. It is obvious that the
number of colonies drastically decreases over time.
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Figure 28: The number of surviving sleeper cells that initiate colonies of proliferating
cells decays exponentially with treatment time. Each data point corresponds a
picture as shown in Fig. 27 where we counted the number of colonies. The line
corresponds to a fitted exponential curve. The data indicate that the number
of colonies decays with rate of 0.844 per week.
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T790M mutation that can be targeted by another drug. As long as the mutations
driving the relapsed tumor can be identified and can be targeted with some drug,
the procedure can be repeated. But it is clear that the approach can not lead to
a cure, since macroscopic tumors inevitably contain therapy resistant mutants: In
first-line therapy, resistance occurs on the background of the wild type. In second-
line therapy, resistance occurs on the background of the fastest growing resistance
mechanism to first-line therapy. Hence, the number of drugs a tumor is resistant
to increases with each round of treatment, making it more and more difficult to
find new treatment options. Nevertheless, the general strategy can lead to a life
extension of several years, and due to the relatively harmless side effects of tar-
geted therapies patients may have a high quality of life during this time. In many
cases, this is much more than could be achieved with chemotherapy or radiation
therapy.
However, if targeted therapy actually aimed at curing patients, it would need
to address not only the wild type but all possible resistance mechanisms as early
as possible. This intent requires complete knowledge about how cells can become
resistant to a specific therapy. Our experimental protocol offers a generic approach
to study the spectrum of resistance mechanisms in cell lines driven by different
activating mutations. In our model system, we found a set of four compounds
to be sufficient to target all resistance mechanisms existing in a population of
given size. Further work needs to investigate if this result also holds in other
EGFR driven cell lines. If so, tumor evolution of EGFR addicted cancers could
be anticipated by targeting the full set of resistance mechanisms already during
first-line therapy.
Apart from targeting all resistant cells, we have to find a way of dealing with
the sleeper cells, which in our model system limit the long-time efficacy of the
treatment. To date, it is unclear how relevant the problem of drug persistence is
in patients, as a relapse usually occurs quickly and is presumably caused by pre-
existing resistant mutants. This means that for now resistance and not persistence
is the critical factor limiting therapy success. It might be that the sleepers are an
artifact of cell cultures, and that in a patient for instance the immune system might
eliminate them. But there is evidence that at least in xenograft mouse models the
knockout of GPX4, a gene that is thought to be crucial for cell survival in the
persister state, inhibits tumor relapse [70]. Therefore the sleeper cells might be
as relevant for the long-term control of the disease in patients as they are in cell
cultures, and future work should address this question.
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There are several potential strategies to clinically cope with surviving sleepers.
The straightforward approach would be to directly target the persister state. Pre-
vious work suggested different targets as possible vulnerabilities of sleeper cells
surviving Erlotinib treatment, such as GPX4 [70], IGF-1R [69] or HDAC [72]. If
these results could be confirmed in our sleepers surviving EOTD treatment, co-
treatment with compounds targeting one or all of the identified vulnerabilities
might eliminate the population completely. Another route to explore might be to
actively wake up the sleeper cells. We showed that, once proliferating again, cells
emerging from sleeper cells are sensitive to Erlotinib mono-therapy. One could
exploit this behavior: There might be a messenger substance (that yet has to be
identified) inducing the transition, and thus re-sensitizing the population to EGFR
inhibition. Obviously, proliferating cells are much more harmful to the organism
than persister cells, which is why in this approach tumor evolution had to be
closely monitored. Finally, our results suggest a third treatment strategy, namely
waiting until all sleepers have decayed over time. A short treatment period with
EOTD would have to be followed by a long Erlotinib maintenance therapy target-
ing sleepers that wake up from the persister state. Assuming a tumor size of 109
cells, a sleeper fraction of 1% and a decay rate as measured of 0.844 per week,
this would mean that after 30 weeks all sleeper cells would have been destroyed
with probability 99.99% – given that the drug is fully available at the tumor site.
As a single surviving persister cell could wake up, expand and cause a relapse, it
is crucial to actually eradicate the population completely. Therefore the treatment
should not be stopped, even if the patient does not exhibit any cancer related
symptoms anymore. In any case, the biology of persistence is very complex (prob-
ably as complex the one of resistance), and future work should aim at further
characterizing sleeper cells and revealing their molecular features.

4 INFERENCE OF CELLULAR STATESFROM S INGLE -CELL L I FET IMES
4.1 motivation: persistence as a way to survive treat-ment
In the previous chapters, we focused on cancer resistance that is due to resistant
mutants existing in a population of sensitive cells prior to any kind of treatment.
But there is another way in which cancer cells can escape from treatment: cells
can enter a cellular state in which they divide very slowly, but are relatively drug
resistant. The degree of resistance as a function of growth rate is currently un-
known. The phenomenon has been shown in the context of resistance to EGFR
inhibition in PC9 cells [69]. Cells in the persistent state are called drug tolerant
persisters (DTPs). Under prolonged treatment, drug resistant mutants can emerge
from DTPs [65]. In section 3.2.4 we showed that, also in our model system, sleeper
cells persisting under therapy limit the long-time efficacy of the treatment. This
means that, even after eliminating all quickly dividing resistant cell types, DTPs
survive and can lead to a relapse. Therefore, persistence might be clinically rele-
vant in the maintenance treatment of cancer patients.
To date, it is not clear what drives the transition to the persister state. We focus
on a study that was conducted on PC9 cells and which points to the hypothesis
that a fraction of the population is always in the slow dividing state – independent
of being treated or not [73] . Using time-lapse automated imaging, the lifetimes
of single cells were recorded. By plotting the histogram of the measured lifetimes,
the authors observed that two peaks emerged – one at small lifetimes (≈ 15 hours)
and another at larger lifetimes (≈ 40− 50 hours). The authors interpreted this ob-
servation as two distinct subpopulations and fitted a model to the histogram with
parameters for cell birth, death and transition to the persistent state. Whereas this
method is an easy approach to determine the parameters governing the underly-
ing process, the analysis does not exploit all of the available information. If one
assumes that the average lifetime is fixed at cell birth and that the state is at least
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to some degree heritable, the distribution of lifetimes along the phylogenetic tree
offers useful information on the probability of switching to or from the persistent
state.
In this chapter, we develop a statistical model to infer heterogeneous growth
rates in a population. As an example of such heterogeneity we assume a mixture of
normal cells and persisters, where the entire population is tracked by imaging and
individual birth and death events are recorded. We ask how to infer the existence
and heritability of states with different growth rates (lifetimes until division) for
such data. We then present a framework to infer both the mean lifetimes and
the switching probabilities from synthetic data and discuss the data required for
applications.
4.2 lifetimes on a hidden markov tree
We consider the population dynamics defined by a hidden Markov model as
sketched in Fig. 29. Consider N cells which live on a binary tree representing
the kinship of the cells: a link between two cells connects a cell to its direct ances-
tor. Each cell is in one out of two discrete states, which we call active (+) for the
quick-dividing and quiescent (−) for the slow dividing state. The generalization
to more states is straightforward. The cellular state is a hidden or latent variable
which cannot be observed directly, but which impacts the observed lifetime: For
each element, a lifetime is drawn from some distribution which depends on the
cellular state. The cellular state is determined at cell division and does not change
during the lifetime of a cell. We consider a Markovian dynamics of these states
{σ1, . . . ,σN}, with a transition probability
Ajk = p(σi = k|par(σi) = j) (47)
between a cell i and its parent par(σi) with j,k ∈ {+,−}. As a starting point, we
assume the lifetimes to be exponentially distributed,
p(τi|σi) =
1
Tσi
exp(−τi/Tσi), σi ∈ {+,−} (48)
with a mean expected lifetime Tσi that is much higher in the quiescent than in the
active state.
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One possible explanation: As response to treatment, the cells switch to another 
cellular state (quiescent state) where they do not divide and have a greater mean 
lifetime than normal cells (active state). 
Our model provides the framework to infer mean lifetimes and transition probabi-
lities for this scenario from single-cell data. It can be extended and generalized to 
incorporate further information, for example the spatial distribution of the cell popu-
lation.  
Figure 29: Single cell lifetimes on a h dden Markov tree. The states σi, active or quiescent,
are not observable and are thus the hidden variables. But they determine from
which distribution the lifetimes τi, which are directly observable, are drawn.
We cannot observe the hidden variables σ = {σ1, . . . ,σN}. Therefore, in the
probability distribution of one specific set of lifetimes we have to sum over all
configurations of the hidden variables,
p(τ) =
∑
σ1={+,−}
· · ·
∑
σN={+,−}
p(τ,σ), (49)
with τ = {τ1, . . . , τN}.
The joint distribution over the lifetimes and the hidden states p(τ,σ) consists
of two parts: First, there is a term describing the transition between states. This
couples the state of each cell with the respective par ntal state. Second, there is
a term describing the probabilities of the lifetimes given the states which we call
emission probabilities. The observed lifetimes of one cell only depend on its own
cellular state – so there is no coupling between neighboring cells. This means that
the joint probability partly factorizes:
p(τ,σ) = p(σ1) ·
N∏
n=2
p(σn|par(σn))︸ ︷︷ ︸
transition probabilities
·
N∏
m=1
p(τm|σm)︸ ︷︷ ︸
emission probabilities
. (50)
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This statistical model model is determined by five independent parameters: The
two mean lifetimes T+ and T− govern the emission probabilities. The transition
probabilities A+k need to be normalized, which means A+− = 1−A++ (analo-
gously for A−k). So the transition probabilities only have two independent param-
eters. There is one more parameter describing the probability of the initial state
p(σ1), which we call pi. If we make these parameter dependencies explicit, we find
p(τ,σ|pi,A++,A−−, T+, T−) =
p(σ1|pi)p(τ1|σ1, T+, T−) ·
N∏
n=2
p(σn|par(σn),A++,A−−) · p(τn|σn, T+, T−).
(51)
Our model can formally be mapped onto an asymmetric Ising problem on a tree,
with states of cells corresponding to spins and rates at which these states change
from one generation to the next generating couplings between these spins. Each
cell can be in two different states, which means that the system of N cells can
take 2N different configurations. Therefore, the number of configurations scales
exponentially in the number of cells. In order to determine the parameters of the
model, we need to calculate expectation values over the configuration space which
means summing over 2N configurations. To do this efficiently, we use an iterative
algorithm starting at the leaves of the tree and progressively proceeding to the
root reducing the number of computation steps to polynomial order. In physics,
this approach is well known as the transfer matrix method. It is also widely used
in the machine learning community, where it is called belief propagation.
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4.3 the backward problem: learning the parameters
To learn the parameters of the model we use a Bayesian approach. We aim at
calculating the Bayesian posterior
p(θ|τ) =
p(τ|θ) · p(θ)
p(τ)
, (52)
where θ = {pi, A++, A−−, T+, T−} is the set of parameters. We want to maximize
p(θ|τ) with respect to θ. From equations (49) and (51) we know how to express
the probability of the data given the parameters as a function of θ. Moreover,
p(τ) does not depend on θ. For the case where we have no prior information
on the parameters, a reasonable assumptions is that the prior probability p(θ) is
flat and does not depend on θ. Under this assumption, the posterior probability
distribution of the parameters conditioned on the observations is proportional to
probability of the observations conditioned on the parameters,
p(θ|τ) ∝ p(τ|θ). (53)
The function p(τ|θ) is called the likelihood of the parameters, and the resulting
set of parameters
θML = argmax
θ
p(τ|θ) (54)
the maximum likelihood estimator. In the following, we seek for the maximum
likelihood estimator given a set of observations subject to the model above.
4.3.1 The expectation maximization algorithm
The expectation maximization (EM) algorithm is a very general and broadly appli-
cable method to calculate maximum likelihood estimates from data with underly-
ing models that have latent variables [74]. In the following, we first give a general
sketch of how EM works. We then apply it to our statistical model. The line of
argument follows [75] where the calculation was performed for a linear hidden
Markov chain designed to model sequential data.
Our goal is to maximize the likelihood p(τ|θ). For convenience, we maximize
the logarithm of the likelihood (called log-likelihood). To do this efficiently, we
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decompose the log-likelihood in two parts. We introduce a probability distribution
q(σ) and rearrange terms
lnp(τ|θ) =
∑
σ
q(σ) lnp(τ|θ)
=
∑
σ
q(σ) ln
p(σ,τ|θ)
p(σ,τ|θ) 1p(τ|θ)
=
∑
σ
q(σ) ln
p(σ,τ|θ)
p(σ|τ,θ)
=
∑
σ
q(σ)
[
ln
p(σ,τ|θ)
q(σ)
− ln
p(σ|τ,θ)
q(σ)
]
= L(q,θ) +DKL(q||p), (55)
where we defined
L(q,θ) =
∑
σ
q(σ) ln
p(σ,τ|θ)
q(σ)
(56)
and the Kullback-Leibler (KL) divergence between q and p
DKL(q||p) = −
∑
σ
q(σ) ln
p(σ|τ,θ)
q(σ)
. (57)
The KL divergence DKL(p||q) has the property DKL(p||q) > 0, where the equality
is saturated if and only if q(σ) = p(σ|τ,θ) [76]. So L(q,θ) is a lower bound
to the log-likelihood, and this bound is obviously saturated if the KL divergence
vanishes.
The EM algorithm for maximizing the log-likelihood exploits this fact. It con-
sists of two steps:
1. E step: The lower bound is maximized with respect to q(σ), but the param-
eters θ = θold remain constant. This is achieved by choosing
q(σ) = p(σ|τ,θold) (58)
such that DKL(p||q) = 0.
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Figure 30: Sketch of how the EM algorithm works. The log-likelihood is decomposed
into two parts. In the E step, the lower bound is maximized with respect to
the auxiliary distribution q. In the M step, the lower bound is maximized
with respect to the parameters θ. If not already at its maximum, this will
lead to an increase in the log-likelihood and a non-vanishing Kullback-Leibler
divergence.
2. M step: The lower bound is maximized with respect to θ. By rearranging
terms a little further, we see that only a part of L depends on θ,
L(q,θ) =
∑
σ
q(σ) ln
p(σ,τ|θ)
q(σ)
(58)
=
∑
σ
p(σ|τ,θold) ln
p(σ,τ|θ)
p(σ|θold)
=
∑
σ
p(σ|τ,θold) lnp(σ,τ|θ)︸ ︷︷ ︸
L(θ,θold)
+ const. (59)
Maximizing L(θ,θold) with respect to θ yields new parameters
θnew ≡ argmaxθ
[
L(θ, θold
]
If these new parameters differ more than some convergence criterion from
the old ones, we set θold = θnew and go back to the E step.
In Fig. 30 we show graphically how the EM algorithm works. Instead of directly
maximizing lnp(τ|θ) = ln
∑
σ
p(τ,σ|θ), we iteratively maximize L(θ,θold). This
has the crucial advantage that the summation over the hidden variables now ap-
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pears outside the logarithm. As we saw earlier, the joint probability distribution
of our model partly factorizes. By plugging in equation (51), we find
L(θ,θold) =∑
σ
p(σ|τ,θold)
(
lnp(σ1|pi) +
N∑
n=2
lnp(σn|par(σn),A++,A−−) +
N∑
m=1
lnp(τn|σn, T+, T−)
)
.
(60)
Crucially, not all terms depend on all hidden variables, and we can partly perform
the summation the latent variables
L(θ,θold) =
∑
σ1
p(σ1|τ,θold) lnp(σ1|pi)
+
N∑
n=2
∑
σn
∑
σn/2
p(σn,σn/2|τ,θ
old) lnp(σn|σn/2,A++,A−−)
+
N∑
m=1
∑
σm
p(σm|τ,θold) lnp(τm|σm, T+, T−), (61)
where we chose a labeling in which node σi is the parent of node σ2i and σ2i+1,
and where n/2 refers to bn2 c. Equation (61) can be easily maximized with respect
to the parameters. We find for the bias of the initial state
pi =
p(σ1 = +|τ,θ)
p(σ1 = +|τ,θ) + p(σ1 = −|τ,θ)
, (62)
for the transition probabilities
A++ =
N∑
n=2
p(σn = +,σn/2 = +|τ,θ)
N∑
n=2
p(σn = +,σn/2 = +|τ,θ) +
N∑
n=2
p(σn = −,σn/2 = +|τ,θ)
, (63)
A−− =
N∑
n=2
p(σn = −,σn/2 = −|τ,θ)
N∑
n=2
p(σn = +,σn/2 = −|τ,θ) +
N∑
n=2
p(σn = −,σn/2 = −|τ,θ)
, (64)
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and, assuming exponentially distributed lifetimes, for the parameters determining
the emission probabilities
T+ =
N∑
n=1
τnp(σn = +|τ,θ)
N∑
n=1
p(σn = +|τ,θ)
, (65)
T− =
N∑
n=1
τnp(σn = −|τ,θ)
N∑
n=1
p(σn = −|τ,θ)
. (66)
The remaining task is to efficiently calculate the marginal probabilities
p(σn|τ,θ) =
∏
j6=n
∑
σj
p(σ,τ)
p(τ)
= c ·
∏
j6=n
∑
σj
p(σ,τ), (67)
where c is a constant which is set by normalization, and p(σn,σn/2|τ,θ), which is
accordingly given by summing over all hidden variables except for σn and σn/2.
4.3.2 Calculating the marginal probabilities using belief propagation
Belief propagation (BP) is an algorithm to efficiently calculate marginal probabili-
ties of nodes in a Bayesian network [77]. The idea is to organize the computation
by introducing variables mi→j(σj) for all neighboring pairs {i, j}. The variable
mi→j(σj) can be interpreted as a message node i sends to node j, about what state
the hidden variable σj should be in based on the information node i has. The
messages are self-consistently defined as
mi→j(σj) =
∑
σi
p(τi|σi) · p(σi|σj)
∏
k∈N(i)\j
mk→i(σi), (68)
where N(i) means the set of neighbors of node i. From the messages, the marginal
probabilities can be calculated as
p(σi|τ) = c · p(τi|σi)
∏
j∈N(i)
mj→i(σi), (69)
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where c is a normalization constant. Also, the two state marginal probabilities can
be expressed in terms of the messages, namely as
p(σn,σn/2) = c · p(τn|σn) · p(τn/2|σn/2) · p(σn|σn/2)∏
k∈N(n)\n/2
mk→n(σn)
∏
j∈N(n/2)\n
mj→n/2(σn/2). (70)
If one has all messages at hand, one can determine all required marginal probabili-
ties. This means that every message only has to be calculated once. So the number
of computations scales polynomially in the number of links M: as each link is
occupied by two messages, the number of messages is 2M. For loop-free graphs,
BP gives the exact marginals. The reason is that in such tree-like structures, one
can start by calculating the messages at the leaves and then progressively go up
the tree. So writing everything in terms of messages is just a re-ordering of terms
in equation (67). In physics, this approach is well known as the transfer matrix
method. This line of argument breaks down once the graphs has loops; in this
case, BP is only an approximate method [78].
In our problem, we have a binary tree, in which each node – except for the
root and the leaves – has exactly two children and one parent. This means that
each message that is sent from the bottom to the top of the tree only depends on
other bottom-up messages. Messages that are sent from the top down the tree,
conversely, depend both on bottom-up and top-down messages (see Fig. 31 for a
sketch). By starting at the leaves, we first calculate all bottom-up messages. We
then go down the tree, starting at the root and calculate all top-down messages.
The message each node sends in direction of the root is given by
mi→i/2(σi/2) =

∑
σi
p(σi|σi/2)p(τi|σi) if i is a leaf∑
σi
p(σi|σi/2)p(τi|σi)m2i→i(σi)m2i+1→i(σi) else.
(71)
Analogously, the top-down message that a node sends to its left child is given by
mi→2i(σ2i) =

∑
σ1
p(σ1)p(σ2|σ1)p(τ1|σ1)m3→1(σ1) for i = 1∑
σi
p(σ2i|σi)p(τi|σi)m2i+1→i(σi)mi/2→i(σi) else,
(72)
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Figure 31: Sketch of messages flowing in and out of node i. As the up messages only
depend on other top messages further down the tree, one first calculates all
top messages. The down messages can then be calculated from the root to the
leaves.
with 2i and 2i+ 1 interchanged for the message that is sent to the right child.
4.4 results and discussion
We test our approach on artificially generated data. We simulate m generations
of cells, which yields a complete binary tree of lifetimes (each node except for the
leaves has exactly two children) of length
N =
m∑
i=0
2i.
We chose the state σ1 of the initial cell randomly and draw a lifetime τ1 from an
exponential distribution with mean T+ if σ1 = + or T− if if σ1 = −. The state of
each subsequent cell is inherited with probabilities A++ or A−− from the parental
state, and the lifetimes are drawn from the respective exponential distribution.
In Fig. 32 we show the inferred parameters for different tree sizes N. Each
dot is an inferred parameter set for one simulated tree of respective length. For
short trees N = 15 and N = 63 (corresponding to 3 and 5 cell generations), the
reconstruction works very poorly. This is because the trees are simply too for
short any transitions to occur. As we chose A++ = A−− = 0.95, it is very unlikely
to find transitions within one tree. Hence the underlying model of two states is
wrong: in each tree, lifetimes are only drawn from one distribution. This is also
why many reconstructed rates fall on the boundaries 0.0 and 1.0. For longer trees,
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Figure 32: Inferred mean lifetimes and switching rates for different nodes N. Each dot
represents a set of inferred parameters for one simulated tree consisting of N
cells. The lines indicate the parameters that were used to simulate the data.
As expected, the reconstruction gets more reliable the longer the trees are. For
shorter trees with N = 15 and N = 63 the reconstructed rates often fall on the
boundaries 0.0 and 1.0.
more transitions per tree occur. Thus, the reconstructed parameters are closer to
the ones we used to generate the data. This means if the tree size is large enough
to reasonable display the transition rates, our method reliably reconstructs the
parameters.
For practical applications it is therefore important to record long phylogenetic
trees of at least seven or eight generations instead of observing many but short
trees. In the context of cancer cells, this implies a considerable experimental effort,
since – on laboratory time scales – cancer cells grow slowly. They usually have a
doubling time of several hours or even days. PC9 cells for example, a fast growing
cancer cell line, divide approximately once per day, so it would be necessary to
monitor a population for a whole week. As a comparison, bacteria divide several
times per hour and a measurement time of four or five hours would be enough to
record a sufficiently long tree of lifetimes. To our knowledge, long trees of cancer
cell lifetimes have not been measured to date: The data that was recorded in [73]
by time-lapse microscopy is only partly publicly available. The published data set
consists of 163 lifetime observations, but the total measurement time was only 90
hours and single lineages were tracked for two or less generations. Therefore, our
method cannot be applied to the data set.
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If we had a data set with sufficiently long trees at hand, a first step would be
to run our algorithm on the data to determine if two or more cellular states can
be observed. If so, the next step would be to modify the distribution of lifetimes.
For simplicity, we used an exponential distribution for the artificial data. In reality,
cells have to pass several phases in cell cycle before they can divide again. So con-
sidering another distribution incorporating this fact, for instance the distribution
of the sum of two exponentially distributed random variables, might be necessary
and would lead to more reliable growth rate estimates.

5 CONCLUS IONS AND OUTLOOK
In this thesis, we studied the evolution of resistance to targeted cancer therapy
from different perspectives. Within a semi-stochastic population genetics model
incorporating a carrying capacity to describe confined tumor growth, we investi-
gated how the statistics of resistant mutants depends on their fitness. We found
that not only the relative birth rate but also the relative death rate determines how
many resistant mutants exist in the population: if at given net growth rate more
sensitive cells die per unit time (implying a larger birth rate), a higher number of
resistant mutants survives on average in the population (see equation (21)). We
further calculated the probability of resistance as a function of population size,
mutation rate and growth rates. We showed that the probability of resistance de-
pends on the fitness of the resistant mutants (the higher the fitness, the higher the
probability of resistance at a given population size). By increasing the population
size or the mutation rate, however, the fitness dependence decreases: no matter
how slowly the resistant mutants grow, if only the population size or the mutation
rate are large enough, resistant mutants exist in the population with probability
close to one (see Fig. 10). We additionally studied how the expectation value
of the number of resistant mutants changes under a splitting procedure as con-
ducted in cell cultures, and determined how slowly growing mutants get fixed in
the population under a Luria-Delbru¨ck dynamics (see equation (45) and Fig. 14).
Our findings explain why resistance is so prevalent when treating cancer pa-
tients with targeted drugs: Resistance is often conferred by single point mutations.
In realistic tumors the point mutation rate times population size is typically much
greater than one, µN  1, which implies a low frequency of resistant mutants
existing prior to any kind of treatment. Therapy then exerts a strong selective pres-
sure favoring resistant cells. Therefore, as long as there is no way of systematically
diagnosing small tumors at early stages of the disease, targeted mono-therapy
cannot be curative for macroscopic, detectable tumors.
If one aims at a therapy with curative intent, knowledge about the complete
spectrum of resistance mechanisms of the respective cancer type is necessary. This
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spectrum may be highly context-dependent, so cancers driven by different molecu-
lar mechanisms become resistant in different ways. We presented an experimental
protocol (see Fig. 17) to systematically amplify all resistance mechanisms to a spe-
cific targeted treatment in a population of given size. Using a specific cell line
as a model, we could show that a set of four compounds is enough to suppress
all mechanisms (for details see section 3.2.3). In principle, one could perform
the experimental protocol on different cell lines and try to identify correspond-
ing compound combinations for those. Although the procedure is conceptually
straightforward, it implies a significant experimental effort.
We further found that sleeper cells limit the long time efficacy of even the most
effective treatment combination. To date, the molecular features of the sleepers
only begin to be understood, and not much is known about their dynamics. We
developed a statistical model to infer growth rates in heterogeneous populations
from single cell lifetime measurements (Fig. 32). If applied to cancer data, our
method could provide clarification to what extent the sleeper state is heritable.
The prospects of cure under targeted therapy
The long-time efficacy of targeted therapies in cancer treatment turned out to be
disappointing so far. Indeed, there exist some conceptual limitations that make
the treatment with targeted cancer drugs extremely challenging, even if effective
compounds are available: Cancerous cells are inherent to the body and thus very
similar to healthy cells. Indeed, they differ from healthy cells only in a few, specific
properties. This is different from agents entirely foreign to an organism, such as
bacteria or viruses. As there are not many independent mechanisms that can
be attacked without harming non-cancerous tissue, tumors are naturally hard to
fight.
To date, it seems as if each tumor only depends on one specific molecular driver,
which complicates treatment with targeted drugs for two reasons. First, the ther-
apy needs to be highly patient-specific. Treatment decisions have to be based
on biomarkers such as point mutations in or amplifications of oncogenes, which
means that samples taken from biopsies have to be sequenced to determine the
genetic subtype. This implies cumbersome diagnostic procedures as well as prac-
tical limitations. Solid tumors are, for instance, spatially heterogeneous. A single
biopsy does not necessarily give a representative picture of the tumor genotype.
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These shortcomings can in principle be overcome by spending more time and ef-
fort.
More severely, the dependence on only one pro-proliferative signal prevents the
implementation of combination therapies targeting independent mechanisms that effec-
tively impede the emergence of resistance in other diseases. In HIV, for instance,
combinations of at least two compounds from different drug classes are adminis-
tered as first-line therapy [79]. Whereas both of the drugs alone already effectively
target the viral infection, each can be overcome by point mutations that turn the
virus insensitive to the treatment, preventing lasting efficacy of mono-therapy [80,
81]. Only the combinatorial delivery of drugs targeting independent mechanisms
enables the long-term control of the disease. This kind of combination therapy
has also been studied theoretically in the context of cancer resistance [82], and it
was shown that if two such independent mechanisms exist, a combination ther-
apy with two targeted drugs can in general lead to long-term tumor regression
[83]: The possibility of a cell existing which harbors two different resistance mech-
anisms is very low. Unfortunately, cancer cells are not susceptible to two kinds of
targeted drugs and targeting independent mechanisms, as in HIV, is impossible in
cancer treatment.
As a result, the focus could be on defining sets of drugs that inhibit a molecular
driver and all accessible resistance mechanisms. In our EGFR-driven model system,
we only found resistance mechanisms which are clinically known: Alteration of
the drug target (R1: EGFR T790M), activation of a downstream signal (R2: NRAS
Q61R) and activation of bypass tracks (R3: HGF amplification; R4: PI3K/mTOR
signaling). If this result holds in other EGFR driven cell lines, the emergence of
resistance could be anticipated by delivering drugs targeting the wild type and all
accessible resistance mechanism already as first-line therapy. This type of combi-
nation therapy is conceptually different from the combination treatment used in
HIV or from the combinations of antibiotics delivered in bacterial infections. It
may offer a way to allow targeted therapy to be less patient specific (the driver
still needs to be identified, but a standardized set of resistance mechanisms could
be co-treated from the start), and drastically increase the long-term efficacy of the
treatment.
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Immune checkpoint blockade – a promising treatment approach
In recent years immunotherapy has been established as another promising alterna-
tive to standard cancer therapy. In contrast to targeted therapies, immunotherapies
do not act against tumors directly, but stimulate the anti-tumor immune response
of the organism. Immune checkpoint blockade could be a treatment approach that
overcomes the conceptual limitations of targeted therapy. Immune checkpoints are
proteins in T-cells that act as switches to regulate the immune response and that
are therefore crucial for self-tolerance [84]: If an inhibitory checkpoint protein
binds to its respective ligand, the T-cell is inactivated and does not attack sur-
rounding cells [85]. Tumors often express genes that code for inhibitory immune
checkpoint ligands and thus ”hide” from immune detection [86]. Immune check-
point blockade, for instance with PD-1 (a checkpoint protein) or PD-L1 (the ligand
of PD-1) inhibitors, works by targeting the checkpoint proteins on the T-cell sur-
face (or their ligands), reactivating T-cell recognition [84]. Some patients benefit
greatly from immune checkpoint inhibition, although at the moment only a sub-
set of patients responds to this kind of therapy: large clinical trials on PD-1 and
PD-L1 inhibition found response rates of 10− 15% [87, 88]. To date, it is unclear
what determines the sensitivity to immunotherapy.
T-cells do not usually attack healthy endogenous cells but only those which
have been infected with viruses or bacteria. But also cancer cells can be recog-
nized if their proteins differ sufficiently from healthy cells. Simply put, the more
the protein content of a cancer cell differs from a healthy cell, the easier it is de-
tected by T-cells. This is mirrored in the response of lung cancer patients to PD-1
blockade. Patients who regularly smoked before diagnosis – meaning that their
cancers typically had more mutations (since tobacco smoke is carcinogenic) – on
average respond better than non-smokers [89]. This implies a completely different
situation compared to targeted therapies. The latter act on very specific genetic
alterations, whereas immune checkpoint blockade can target many different mu-
tations at a time. Therefore, it is much more robust against genetic heterogeneity
in large populations which limits the long-time efficacy of targeted therapies.
Immunotherapy also is very interesting from a modeling perspective. The in-
teraction with the immune system adds an additional layer of complexity to the
process of tumor evolution. This makes the dynamics harder to model and pre-
dict. Probably not all tumors are in principle susceptible to immunotherapy. If one
were able to foresee which patients respond to immunotherapy, treatment efficacy
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could be drastically improved. A first approach towards this goal is based on a
fitness model for neoantigens and correctly predicts the response to checkpoint
blockade immunotherapy in three patient cohorts [47]. Future work in this direc-
tion will hopefully lead to a more conceptual understanding of the requirements
for successful immunotherapy.

GLOSSARY
adenocarcinoma Type of cancer started by glandular cells lining some organs.
Adenocarcinomas are often found in the breast, lung, prostate, or colon.
(gene) amplification An increased copy number of a gene in the genome
compared to a normal diploid organism. The amplification of a gene can lead to
more RNA and thus a higher production of proteins made from the gene (see also
overexpression).
apoptosis Cellular program of controlled cell death which can be triggered by
extra-cellular stimuli (also called cell suicide). It is crucial for tissue organization
and renewal: unwanted, DNA damaged, or superfluous cells can be eliminated in
a highly ordered physiological process that does not harm surrounding cells.
cellular receptor Cell surface protein that mediates the communication of a
cell with its environment. A signal is transmitted by binding to specific extracellu-
lar molecules (e.g. hormones, growth factors, or nutrients). Binding activates the
receptor, for instance by dimerization with another receptor or by a conformational
change. This in turn changes how the intracellular part of the receptor interacts
with other proteins within the cell and triggers a chemical signaling cascade. De-
pending on which cellular receptor binds to which ligand, different physiological
outcomes occurs, for instance apoptosis, adhesion, differentiation, proliferation, or
migration.
chromosomal rearrangement Genetic alteration that changes the structure
of a native chromosome. Chromosomal rearrangements are usually caused by
DNA double strand breaks and consecutive rejoining of the broken strands in
an abnormal way. By that, the usual order in which genes are arranged on a
chromosome is disrupted. Chromosomal rearrangements can involve deletions,
duplications, inversions, and translocations.
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crystal violet Bright violet dye that binds to proteins and DNA. It is for
example used to stain cells grown in cell culture to make them easily visible.
enu (n-ethyl-n-nitrosourea) Chemical mutagen that increases the muta-
tion rate. It causes heritable mutations by transferring ethyl groups to nitrogen
or oxygen sites on each of the four deoxyribonucleic acids. During the next cell
division, these additional ethyl groups lead to a misreading of the bases resulting
in mutations that get fixed in the next generations.
growth factor Protein triggering cell growth and proliferation by binding to
a cellular receptor.
(protein) kinase An enzyme modifying proteins by catalyzing the transfer
of a phosphate group from a donor (such as ADP) to a substrate. In cell signaling
protein kinases act as molecular switches: the addition of a phosphate group often
leads to a conformational change activating the protein.
mapk pathway Example of a signaling circuit that transmits a signal from a
cell surface receptor to the cell nucleus. It consists of a chain of intracellular
proteins that, upon activation of a receptor such as EGFR, gradually induces kinase
phosphorylation (RAS activation → RAF activation → MEK activation → ERK
activation). Phosphorylated ERK activates transcription factors that are important
for cell growth, proliferation, and survival.
metastasis A tumor consisting of cells which derive from a malignant growth
somewhere else in the body. For example, if a lung cancer spreads to the liver, the
cancerous cells there (forming a metastasis) are lung cells and not liver cells.
molecular driver Specific genetic alteration that is necessary for the survival
and the proliferation of a cancer cell. Drivers can be point mutations in genes that
code for cellular receptors or other components of the cellular signaling network,
but also amplifications or overexpressions of genes controlling proliferation.
neoplasm (neoplastic tissue) Tissue that grows abnormally and excessively.
Depending on their behavior neoplasms are grouped in different classes. Malig-
nant neoplasms that invade and destroy surrounding tissue are called tumors.
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oncogene A mutated form of a normal gene that induces cancer. Genes that
upon mutation can turn to oncogenes are called proto-oncogenes.
oncovirus A virus that can cause cancer by introducing genetic material to
the DNA or RNA of a host. Some well-known representatives are the human
papillomavirus (increasing the risk of cervical cancer), the Epstein-Barr virus (in-
ducing, for instance, Hodgkin’s lymphoma or gastric cancer), or the hepatitis C
virus (inducing liver cancer).
overexpression Refers to a situation where more RNA or proteins are made
from a specific gene in a cell than normal. Overexpression may be caused by a
genetic amplification (which means that more copies are transcribed) or by dereg-
ulation of genes that control transcription.
passage One cycle of seeding, expanding, and (when the population has filled
the culture vessel) splitting a cell culture.
phosphorylation Covalent binding of a phosphate group to an organic com-
pound such as a protein. A prominent example is the phosphorylation of adeno-
sine diphosphate (ADP) to adenosine triphosphate (ATP), a process of storing and
transferring energy as used by all living cells. Phosphorylation often activates a
protein, a process that is crucial in cell signaling.
somatic mutation Mutation that occurs in the genome outside the germ line
and that is acquired during the lifetime of an organism. By definition, somatic
mutations are not passed on to the next generation.
tumor suppressor A protein that negatively regulates the cell cycle or pro-
motes apoptosis, thus constraining cell proliferation. A mutation or deletion in
a gene coding for a tumor suppressor affecting its function is a crucial step in
tumorigenesis.
tumorigenesis The multi-step process of tumor formation involving many
independent genetic alterations (see ’The hallmarks of cancer’, section 1.1.2).
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western blot Experimental method to examine the protein levels in cells. In
brief, it works as follows: Cells are seeded in different culture conditions (for in-
stance with and without treatment). After a defined treatment time, cell lysis is
induced by a lysis buffer which breaks up the membrane structure of the cells. The
solution containing the cell content is transferred to an agarose gel. By employing
an electrical field, the molecules are separated by size and subsequently, by apply-
ing an electrical field in the orthogonal direction, transferred to a membrane. With
the help of antibodies that bind specifically to the protein of interest and which are
fluorescently labeled, the amount of protein can be visualized. Importantly, one
uses additional antibodies, that only bind to the phosphorylated form (meaning
the active form) of the protein of interest, so that one can not only monitor the
total protein content (for example total EGFR or tEGFR) but also if the respective
protein is in its active state (for example phosphorylated EGFR or pEGFR). The
name western blot alludes to Edwin Southern, who invented the blotting technique
for DNA fragments – a method he called southern blot. Subsequent variations of
the protocol to detect RNA and proteins were called northern blot and western
blot, respectively.
whole exome sequencing (wes) Technique to sequence the protein-coding
part of the genome. In humans only about 1% of the genome codes for proteins
(according to approximately 30 million base pairs), which is why WES is much
cheaper compared to sequencing a whole genome. WES consists of two consecu-
tive steps: At first the exonic parts of the genome are selectively enriched. After
that the exonic DNA is sequenced, usually using some high-throughput sequenc-
ing technology.
xenograft Tissue taken from a donor of one species that is transferred to
a recipient of another species. In cancer research human tumor cells are often
introduced into mice, for instance to study the in-vivo response of a cell line to a
drug. These mice are then called xenograft mouse models.
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